{"study_id": 103284, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the relationship between end-of-treatment levels of hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg) and outcomes after nucleo(s)tide analogue (NA) therapy cessation, including alanine aminotransferase (ALT) flare rates.", "results_summary": "Lower HBcrAg and HBsAg levels were associated with higher rates of sustained virologic response and HBsAg loss, and lower rates of ALT flares. The SCALE-B score, incorporating these factors, effectively stratified risk for favorable outcomes.", "population_specificity": "572 patients (80% Asian, 17% hepatitis B e antigen positive at therapy start) from centers in Asia and Europe.", "effective_dosage": "Not specified", "study_duration": "Median treatment duration was 295 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:50.099140+00:00"}
{"study_id": 103303, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to quantify the dose-response relationship between weight loss and improvements in NAFLD biomarkers.", "results_summary": "The study found that every 1 kg of weight loss was associated with a 0.83-unit improvement in NAFLD biomarkers, with clinically significant improvements even at modest weight loss. Greater weight loss correlated with greater improvements.", "population_specificity": "People with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 6 months (interquartile range: 6 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:50.404873+00:00"}
{"study_id": 103304, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to establish Korean reference ranges for serum IGF-I and IGFBP-3 and assess their relationship with clinical parameters, including alanine transferase.", "results_summary": "The study found that the IGF-I/IGFBP-3 ratio was positively associated with alanine transferase levels after adjusting for age, suggesting a potential link between IGF-I and liver function. No direct effects or outcomes of alanine itself were reported.", "population_specificity": "354 healthy Korean adults (180 male, 174 female) aged 21-70 years.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:51.727402+00:00"}
{"study_id": 103306, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the use of machine learning algorithms to predict coagulopathy in patients with spontaneous intracerebral hemorrhage, with alanine transaminase identified as one of the predictive parameters.", "results_summary": "Alanine transaminase was identified as a major predictor of acute coagulopathy in patients with spontaneous intracerebral hemorrhage, but the study did not assess its direct effects or efficacy as a supplement.", "population_specificity": "Patients with acute spontaneous intracerebral hemorrhage (n=1668) from three medical centers, excluding those on antithrombotic therapies.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.044641+00:00"}
{"study_id": 103305, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical course of COVID-19 during pregnancy and its impact on maternal and perinatal outcomes, with a focus on predictors like alanine aminotransferase levels.", "results_summary": "The study found that increased alanine aminotransferase levels were a predictor of severe COVID-19 in pregnant women, but no direct effects or outcomes related to alanine supplementation were reported.", "population_specificity": "Pregnant women with PCR-confirmed SARS-CoV-2 infection and their neonates.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.221489+00:00"}
{"study_id": 103308, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of SGLT2 inhibitors on hepatic parameters, specifically alanine aminotransferase (ALT) levels.", "results_summary": "The meta-analysis found that SGLT2 inhibitors significantly lowered ALT levels (WMD: -4.79 U/L, 95% CI: -6.10, -3.47), indicating a potential benefit for hepatic function.", "population_specificity": "Not specified in the abstract (likely patients in randomized controlled trials).", "effective_dosage": "Not mentioned in the abstract.", "study_duration": "Not mentioned in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.459137+00:00"}
{"study_id": 103307, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, safety, tolerability, and efficacy of ceritinib in Chinese patients with ALK+ NSCLC who had progressed after crizotinib and prior chemotherapy.", "results_summary": "The study found that ceritinib's pharmacokinetics in Chinese patients were consistent with global data, was well tolerated, and showed durable responses in this population.", "population_specificity": "Adult Chinese patients with stage IIIB or IV ALK+ NSCLC pretreated with crizotinib and \u22642 prior lines of chemotherapy.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:56.743604+00:00"}
{"study_id": 103309, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of metformin on markers of inflammation and diabetic kidney disease in adolescents with type 1 diabetes, including assessments related to alanine aminotransferase.", "results_summary": "The study found that metformin was associated with a 13.9 mL/min/1.73 m\u00b2 change in eGFR, but specific results regarding alanine aminotransferase or other alanine-related outcomes were not detailed in the abstract.", "population_specificity": "Adolescents aged 12-21 years with type 1 diabetes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:56.815004+00:00"}
{"study_id": 103311, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify hematological indicators, including alanine aminotransferase (ALT), for managing COVID-19 severity.", "results_summary": "The study found a positive correlation between ALT and prothrombin time (PT) in severely and critically ill COVID-19 patients, suggesting ALT as an important indicator for disease management.", "population_specificity": "52 COVID-19 patients admitted to a designated hospital, including moderately, severely, and critically ill cases, with age stratification (older and younger than 50).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:58.248584+00:00"}
{"study_id": 103310, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify metabolite biomarkers, including alanine, that could differentiate pre-diabetes and type 2 diabetes mellitus (T2DM) from healthy individuals.", "results_summary": "The study found that alanine levels were higher in prediabetic patients compared to healthy controls, suggesting it may serve as a biomarker for pre-diabetes. However, its role in T2DM was less clear, as it was not significantly elevated in T2DM patients.", "population_specificity": "Healthy individuals, pre-diabetes patients, and T2DM patients.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:58.636456+00:00"}
{"study_id": 103312, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify metabolic changes and pathways related to osteoarthritis (OA), including the role of alanine as a potential biomarker.", "results_summary": "The study found that perturbations in amino acid metabolism, including alanine, were significantly related to OA pathogenesis. Alanine was identified as a potential biomarker to distinguish OA patients from healthy individuals.", "population_specificity": "Animal models and humans with osteoarthritis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:59.817503+00:00"}
{"study_id": 103314, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to characterize the clinical and biochemical course of anabolic androgenic steroid (AAS)-induced liver injury (DILI) and associated renal dysfunction, including management strategies.", "results_summary": "The study found that AAS DILI commonly presents with jaundice and pruritus, with peak bilirubin levels occurring 28 days after stopping AAS. Liver biopsies showed bland canalicular cholestasis, and 43% of patients developed kidney injury. No fatalities or liver transplants were reported.", "population_specificity": "Patients with AAS-induced liver injury and associated renal dysfunction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.783826+00:00"}
{"study_id": 103313, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine screening practices, annual incidence, and clinical characteristics of NAFLD in children, with a focus on alanine aminotransferase levels as a marker.", "results_summary": "The study found that 12.3% of children with overweight or obesity and elevated alanine aminotransferase (>30 U/L) received further workup for NAFLD, and the incidence of NAFLD diagnosis increased from 36.0 to 58.2 per 100,000 between 2009 and 2018.", "population_specificity": "Children aged 5-18 with overweight or obesity in an integrated community health system in southern California.", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.960851+00:00"}
{"study_id": 103315, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 12, "quality_score": 75, "study_goal": "The researchers aimed to assess the diagnostic accuracy of routine laboratory tests, including alanine aminotransferase (ALT), as triage tests for COVID-19.", "results_summary": "The study found that an increase in alanine aminotransferase (ALT) had a summary sensitivity of 12% (95% CI 3% to 34%) at median specificity (92%), indicating low diagnostic accuracy for COVID-19. The evidence was rated as low-certainty due to heterogeneity and methodological limitations.", "population_specificity": "Hospitalized patients with suspected or confirmed COVID-19.", "effective_dosage": "Not applicable (laboratory marker, not a supplement).", "study_duration": "Not applicable (single-time or repeated laboratory measurements).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:04.019975+00:00"}
{"study_id": 103317, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the genetic origins of primary hypobetalipoproteinemia and its association with liver steatosis and liver injury.", "results_summary": "The study found that a polygenic origin of hypobetalipoproteinemia is linked to a lower risk of liver steatosis and liver injury compared to monogenic hypobetalipoproteinemia, suggesting the polygenic risk score can help personalize patient follow-up.", "population_specificity": "Patients with primary hypobetalipoproteinemia (LDL-C concentrations below the fifth percentile).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:04.850978+00:00"}
{"study_id": 103316, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of NUC-1031 (a phosphoramidate transformation of gemcitabine) in combination with cisplatin for treating advanced biliary tract cancer (ABC).", "results_summary": "The study demonstrated a favorable safety profile for NUC-1031 combined with cisplatin, with 725 mg/m\u00b2 identified as the recommended phase II dose. Efficacy outcomes were not explicitly detailed in the abstract.", "population_specificity": "Patients with untreated advanced biliary tract cancer (ABC), including cholangiocarcinoma, ampullary, and gallbladder cancer, with an Eastern Cooperative Oncology Group performance status of 0-1.", "effective_dosage": "625 mg/m\u00b2 and 725 mg/m\u00b2 of NUC-1031.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:05.539633+00:00"}
{"study_id": 103318, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to estimate the proportion of people with chronic HBV infection eligible for antiviral treatment worldwide, based on WHO 2015 guidelines, including the role of abnormal alanine aminotransferase (ALT) levels as a diagnostic marker.", "results_summary": "The study found that 30.8% of participants had ALT above the upper limit of normal, and 19% were eligible for treatment according to WHO guidelines, with higher eligibility in clinic settings (25%) compared to community settings (12%).", "population_specificity": "People with chronic HBV infection, including those in community and clinic settings.", "effective_dosage": "Not available", "study_duration": "Not applicable (meta-analysis of existing studies)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:06.278392+00:00"}
{"study_id": 103320, "supplement_id": 863, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the potential role of \u03b2-N-methylamino-L-alanine (a form of alanine) as a genotoxic environmental trigger for neurodegenerative disorders like ALS-PDC.", "results_summary": "The study suggests that \u03b2-N-methylamino-L-alanine, metabolized to formaldehyde, may contribute to neurodegenerative disease through DNA damage, epigenetic changes, and neuronal degeneration, with effects appearing years or decades after early-life exposure.", "population_specificity": "Chamorros of Guam-USA, Japanese residents of the Kii Peninsula, and Auyu-Jakai linguistic groups of Papua-Indonesia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:07.306920+00:00"}
{"study_id": 103321, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of whole grain wheat (WGW) versus refined wheat (RW) on fecal microbiota composition and functionality, and correlate these changes with liver health parameters, including alanine transaminase levels.", "results_summary": "The WGW intervention increased the relative abundance of certain bacterial taxa (Ruminococcaceae family) and predicted fermentation pathways, with a positive correlation between changes in Ruminococcaceae_NK4A214_group and liver fat in both WGW and RW groups. However, direct effects on alanine transaminase or other liver enzymes were not explicitly detailed.", "population_specificity": "Middle-aged overweight and obese adults (45-70 years, BMI 25-35 kg/m\u00b2).", "effective_dosage": "98 g/d of WGW or RW.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:08.772841+00:00"}
{"study_id": 103324, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the safety, tolerability, and preliminary efficacy of combining pembrolizumab, hypofractionated stereotactic irradiation, and bevacizumab in patients with recurrent high-grade gliomas, not specifically focused on Alanine.", "results_summary": "The study reported increased alanine aminotransferase as a treatment-related adverse event in 25% of patients, but the focus was not on Alanine's effects.", "population_specificity": "Patients with recurrent glioblastoma or anaplastic astrocytoma.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Not specified for Alanine-related outcomes.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:11.890426+00:00"}
{"study_id": 103322, "supplement_id": 863, "safety_score": "30", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the liver-related safety risks of onasemnogene abeparvovec (OA) in patients with spinal muscular atrophy (SMA), focusing on identifying and managing drug-induced liver injury.", "results_summary": "The study found that 90% of patients had elevated liver function test results, with 34% in clinical trials and 23% in MAP/RESTORE reporting liver-associated adverse events. While all events resolved, serious acute liver injury occurred in two patients, highlighting hepatotoxicity as a known risk of OA.", "population_specificity": "Patients with spinal muscular atrophy (SMA), including infants and young children, across clinical trials, a managed access program, and commercial use.", "effective_dosage": "Not specified", "study_duration": "Prednisolone treatment duration varied (33-229 days), with most receiving it for 60-120 days.", "interactions": "Potentially hepatotoxic concomitant medications were used by over 40% of patients.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:14.094141+00:00"}
{"study_id": 103323, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe liver injury and identify risk factors for liver function abnormalities in COVID-19 patients without chronic liver diseases, with a focus on markers like alanine aminotransferase (ALT).", "results_summary": "The study found that 29.4% of COVID-19 patients without chronic liver disease had abnormal liver function on admission, with ALT elevation in 11.0%. During hospitalization, 56.3% showed liver function abnormalities, including ALT elevation in 36.8%. Risk factors included age over 50, male sex, and lopinavir-ritonavir use.", "population_specificity": "228 confirmed COVID-19 patients without chronic liver diseases from ten hospitals in Jiangsu, China.", "effective_dosage": "Not specified", "study_duration": "Duration of hospitalization (not explicitly stated)", "interactions": "Lopinavir-ritonavir was associated with increased risk of liver function abnormality, while interferon \u03b1-2b inhalation reduced the risk.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:14.102400+00:00"}
{"study_id": 103325, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of cilofexor, firsocostat, and selonsertib, alone or in combination, for improving fibrosis and NASH activity in patients with advanced liver disease.", "results_summary": "The combination of cilofexor and firsocostat showed significant improvements in NASH activity, liver biochemistry, and noninvasive markers, with a potential antifibrotic effect, though the primary endpoint of fibrosis improvement was not statistically significant. Other combinations and monotherapies did not show significant benefits over placebo.", "population_specificity": "Patients with bridging fibrosis or compensated cirrhosis (F3-F4) due to NASH.", "effective_dosage": "Cilofexor 30 mg, firsocostat 20 mg, selonsertib 18 mg, once daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:14.214980+00:00"}
{"study_id": 103327, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of propolis (not Alanine) on hepatic steatosis and fibrosis in patients with NAFLD.", "results_summary": "Propolis significantly improved hepatic steatosis and reduced liver stiffness and hs-CRP levels compared to placebo, but no significant changes were observed in serum levels of fasting blood sugar, alanine aminotransferase, or other metabolic markers.", "population_specificity": "54 patients with nonalcoholic fatty liver disease (NAFLD)", "effective_dosage": "250 mg twice daily", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:14.617712+00:00"}
{"study_id": 103326, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of personalised versus standard dosimetry of selective internal radiation therapy with yttrium-90-loaded glass microspheres in patients with hepatocellular carcinoma, not specifically related to Alanine.", "results_summary": "The study found that personalised dosimetry significantly improved the objective response rate compared to standard dosimetry in patients with locally advanced hepatocellular carcinoma. Safety profiles showed some adverse events, but the study did not focus on Alanine.", "population_specificity": "Patients aged 18 or older with unresectable locally advanced hepatocellular carcinoma, at least one measurable lesion \u22657 cm, and no extrahepatic spread (except lymph nodes of the hilum).", "effective_dosage": "Not mentioned (study focused on radiation dosimetry, not Alanine).", "study_duration": "Not mentioned (study assessed outcomes at 3 months post-intervention).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:15.368597+00:00"}
{"study_id": 103328, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to assess the effect of long-term empagliflozin therapy on hepatic inflammation, function, and fibrosis in patients with NAFLD complicated by type 2 diabetes mellitus.", "results_summary": "One-year empagliflozin treatment significantly improved markers of hepatic inflammation, function, and fibrosis, including weight, BMI, liver enzymes, glucose metabolism, and insulin resistance. The ALBI score, FIB-4 index, and Mac-2 Binding Protein Glucosylation Isomer showed significant improvements.", "population_specificity": "Patients with NAFLD complicated by type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:17.225831+00:00"}
{"study_id": 103329, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to examine the Mediterranean diet's effect on metabolic syndrome incidence, components, risk factors, and related comorbidities, not specifically Alanine.", "results_summary": "The abstract does not mention Alanine or its effects; it focuses on the Mediterranean diet's impact on metabolic health outcomes.", "population_specificity": "Adults in controlled trials comparing the Mediterranean diet with no treatment, usual care, or different diets.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:18.076821+00:00"}
{"study_id": 103330, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and pharmacokinetics of a high dose of atogepant, focusing on its potential impact on serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found that atogepant was generally well-tolerated with no clinically meaningful ALT elevations, and adverse events were mostly mild. No significant differences in ALT changes were observed between atogepant and placebo groups.", "population_specificity": "Healthy participants aged 23-55 years.", "effective_dosage": "170 mg once daily.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:23.093671+00:00"}
{"study_id": 103334, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not assess Alanine; it evaluates the impact of atorvastatin and/or aspirin on clinical deterioration in COVID-19 patients.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Hospitalized COVID-19 patients aged 40-75 years with WHO clinical improvement ordinal score 3-5.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "Not applicable", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:23.853331+00:00"}
{"study_id": 103333, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and tolerability of selinexor combined with carboplatin and paclitaxel chemotherapy in patients with ovarian and endometrial cancers, not specifically studying Alanine.", "results_summary": "The study reported common treatment-related adverse events, including alanine transaminase increase (43% grade 3/4), but did not focus on Alanine's effects.", "population_specificity": "Patients with serous ovarian cancer and endometrial cancer (including carcinosarcomas).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:24.218510+00:00"}
{"study_id": 103331, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop a risk assessment system for HIV-infected patients with comorbid talaromycosis, using factors including alanine transaminase levels to predict mortality risk.", "results_summary": "The study found that aspartate aminotransferase/alanine transaminase ratio, among other factors, was a valid predictor of death risk in HIV-infected patients with talaromycosis. The developed risk scoring system showed effective discrimination (AUC = 0.860 in development, 0.793 in validation).", "population_specificity": "HIV-infected patients with talaromycosis in China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:24.496860+00:00"}
{"study_id": 103332, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to define best practices for detecting, monitoring, diagnosing, and managing suspected drug-induced liver injury (DILI) in patients with chronic liver diseases (CLDs) during clinical trials.", "results_summary": "The study concluded that current DILI monitoring criteria may lead to unnecessary drug cessation in CLD patients and recommended disease-specific laboratory criteria, revised baseline values, and more sensitive liver function tests to better identify DILI.", "population_specificity": "Patients with chronic liver diseases (CLDs), including hepatitis C virus (HCV), hepatitis B virus (HBV), and nonalcoholic steatohepatitis (NASH) with or without cirrhosis.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:25.449502+00:00"}
{"study_id": 103336, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to examine the role of alanine and other metabolites in the diagnosis, prognosis, treatment, and recurrence of ovarian cancer using metabolomics.", "results_summary": "The study found that alanine was down-regulated in ovarian cancer patients, suggesting its potential as a diagnostic biomarker. However, combinations of multiple metabolites, including phospholipids, showed higher diagnostic accuracy than alanine alone.", "population_specificity": "Humans with ovarian cancer", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:25.527450+00:00"}
{"study_id": 103335, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the association between overweight and COVID-19 severity, drug response, and clinical outcomes, not specifically Alanine.", "results_summary": "The study found that overweight COVID-19 patients under 45 years old had higher proportions of increased alanine aminotransferase, among other clinical features, but did not focus on Alanine's effects.", "population_specificity": "COVID-19 patients admitted to Union Hospital in Wuhan, China, excluding obese, underweight, under 18, pregnant, or hospitalized patients.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:26.001628+00:00"}
{"study_id": 103337, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of various amino acids, including alanine, on postprandial glucose and insulin concentrations in healthy adults and individuals with obesity or type 2 diabetes.", "results_summary": "Oral ingestion of alanine induced an insulin response but did not alter glucose concentrations in healthy participants. In individuals with type 2 diabetes or obesity, alanine ingestion or intravenous infusion stimulated insulin release and decreased glucose levels.", "population_specificity": "Healthy adults and individuals with obesity and/or type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Acute (single ingestion/infusion)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:26.838542+00:00"}
{"study_id": 103338, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to evaluate the comparative safety and efficacy of the lopinavir + ritonavir (L/R) combination in the management of COVID-19, not Alanine.", "results_summary": "The study found no discernible beneficial effect of L/R compared to standard of care in terms of disease progression, mortality, or virological cure, but noted some benefits in hospital stay duration and time to virological cure. No significant efficacy difference was observed between L/R and other antivirals like hydroxychloroquine or arbidol.", "population_specificity": "Patients with COVID-19", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:31.858435+00:00"}
{"study_id": 103340, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore the role of alanine and other amino acids in the pathogenesis and detection of nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that altered plasma levels of alanine, along with other amino acids, are associated with NAFLD and may serve as biomarkers for early detection and severity assessment. Excess alanine availability may contribute to intrahepatic fat accumulation.", "population_specificity": "Individuals with or at risk of nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:31.967750+00:00"}
{"study_id": 103339, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine whether improving hepatic fibrosis and inflammation in chronic hepatitis C patients after DAA treatment would increase 25-hydroxyVD levels, indirectly assessing liver function markers like alanine aminotransferase.", "results_summary": "Alanine aminotransferase levels significantly decreased post-treatment, indicating reduced liver inflammation, but vitamin D levels did not improve despite fibrosis attenuation. Over 80% of patients remained vitamin D insufficient/deficient.", "population_specificity": "80 chronic hepatitis C patients (17 with chronic hepatitis, 63 with cirrhosis).", "effective_dosage": "Not specified for alanine.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:32.257231+00:00"}
{"study_id": 103342, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to explore the effectiveness and safety of tocilizumab for treating COVID-19, not Alanine.", "results_summary": "The study found no significant influence of tocilizumab on alanine aminotransferase (ALT) levels in COVID-19 patients.", "population_specificity": "COVID-19 patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:32.366907+00:00"}
{"study_id": 103343, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study does not investigate Alanine; it focuses on the effect of Famotidine on COVID-19 recovery.", "results_summary": "The abstract does not report any findings related to Alanine.", "population_specificity": "COVID-19 patients with positive PCR tests, excluding those with specific conditions like liver disease or elevated Alanine transaminase levels.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:32.882217+00:00"}
{"study_id": 103341, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the prevalence of Plasmodium spp. and HBV co-infection in endemic areas and assess related risk factors.", "results_summary": "The pooled prevalence estimate of Plasmodium spp. and HBV co-infection was 6% (95% CI 4-7%), indicating a notable co-infection rate in the studied populations. The study highlights the need for further research on interactions between these pathogens.", "population_specificity": "People living in endemic areas of Plasmodium spp. and HBV.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:33.001999+00:00"}
{"study_id": 103344, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to validate previously identified metabolites, including alanine, and assess their ability to predict hypoxic-ischemic encephalopathy (HIE) in neonates, both individually and in combination with clinical data.", "results_summary": "Alanine was identified as one of the primary metabolite predictors for the development of HIE. When combined with clinical data, it significantly improved predictive accuracy (AUC 0.96).", "population_specificity": "Term neonates with signs of perinatal asphyxia, with and without HIE, and matched controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:34.494295+00:00"}
{"study_id": 103345, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the real-world effectiveness of dulaglutide versus liraglutide in glycemic control and other metabolic parameters, including alanine aminotransferase levels, in type 2 diabetes patients.", "results_summary": "Both dulaglutide and liraglutide significantly reduced HbA1c, weight, and alanine aminotransferase levels, with dulaglutide showing superior glycemic control. The treatments had comparable effects on weight, blood pressure, and liver and renal functions.", "population_specificity": "Type 2 diabetes patients in Taiwan treated during 2016-2018.", "effective_dosage": "Not specified in the abstract.", "study_duration": "1-year follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:36.975218+00:00"}
{"study_id": 103350, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate liver safety findings in healthy adults consuming therapeutic doses of CBD, including potential correlations between transaminase elevations and baseline characteristics, pharmacogenetic, and pharmacokinetic data.", "results_summary": "Seven (44%) participants experienced elevated serum ALT levels, with five (31%) meeting criteria for drug-induced liver injury. No correlation was found between ALT elevations and baseline characteristics, CYP2C19 genotype, or CBD plasma concentrations.", "population_specificity": "Healthy adults", "effective_dosage": "1,500 mg/day", "study_duration": "~3.5 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:39.905033+00:00"}
{"study_id": 103347, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the prognostic utility of the prognostic nutritional index (PNI), which includes alanine transaminase (ALT) levels, in nasopharyngeal carcinoma (NPC) patients.", "results_summary": "The study found that a lower ALT level was associated with a lower PNI level, which in turn correlated with worse overall survival, progression-free survival, and distant metastasis-free survival in NPC patients. The PNI, including ALT, was identified as a promising prognostic biomarker.", "population_specificity": "Patients with nasopharyngeal carcinoma (3631 participants across 8 studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:39.949532+00:00"}
{"study_id": 103352, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers aimed to report a rare case of gamma glutamyl transpeptidase (GGT) elevation induced by atorvastatin, unrelated to Alanine.", "results_summary": "The study found that atorvastatin caused a marked elevation in GGT levels without hyperbilirubinemia or other abnormalities, which normalized after cessation. The abstract does not discuss Alanine.", "population_specificity": "A 47-year-old male with dyslipidemia.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:40.288991+00:00"}
{"study_id": 103351, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare metabolic responses, including alanine utilization, during hypoglycemia versus euglycemia in adults with type 1 diabetes during exercise.", "results_summary": "Hypoglycemia during exercise increased utilization of glucogenic amino acids, including alanine, suggesting altered metabolic stress. However, physiological responses to exercise masked symptomatic recognition of hypoglycemia.", "population_specificity": "Thirteen adults with type 1 diabetes (age 36\u00b115 years, diabetes duration 15\u00b112 years).", "effective_dosage": "Not specified", "study_duration": "Maximum of 45 minutes of submaximal exercise", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:40.802858+00:00"}
{"study_id": 103346, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the safety and efficacy of proton beam radiotherapy (PBT) versus radiofrequency ablation (RFA) in patients with recurrent/residual hepatocellular carcinoma (rHCC), not specifically to evaluate alanine.", "results_summary": "The study found that PBT was non-inferior to RFA in terms of 2-year local progression-free survival (LPFS) and reported adverse events, including increased alanine aminotransferase levels (96.4%) in the RFA group. No Grade 4 adverse events or mortality were noted.", "population_specificity": "Patients with recurrent/residual hepatocellular carcinoma (rHCC) (size <3 cm, number \u22642).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:41.649647+00:00"}
{"study_id": 103348, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the long-term safety, tolerability, and effectiveness of lomitapide in adults with homozygous familial hypercholesterolemia (HoFH).", "results_summary": "The study found a mean 33% reduction in LDL-C, with 65.4% achieving LDL-C <100 mg/dL and 41.1% achieving LDL-C <70 mg/dL. Adverse events were common (75.7%), but the incidence of serious AEs and hepatic events was lower than in phase III trials, potentially due to the lower median dose.", "population_specificity": "Adults with homozygous familial hypercholesterolemia (HoFH) (N = 187, mean age 52.2 \u00b1 15.3 years).", "effective_dosage": "Median dose of 10 mg (range: 5 mg QOD to 40 mg QD).", "study_duration": "Up to 5.9 years (median 1.98 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:41.958041+00:00"}
{"study_id": 103353, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the efficacy and safety of silymarin (not Alanine) for managing glucose/lipid metabolic dysfunction in patients.", "results_summary": "Silymarin significantly improved glucose and lipid metabolism markers (e.g., fasting blood glucose, cholesterol) but had no impact on liver/kidney function indicators like alanine transaminase or creatinine. It was deemed safe with no increased complication rates.", "population_specificity": "Patients with glucose/lipid metabolic dysfunction (1,358 participants across 16 studies).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Subgroup analysis noted effects after >3 months of use.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:42.749485+00:00"}
{"study_id": 103354, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to summarize the evidence on the effects of SGLT2 inhibitors, including their impact on serum alanine levels, in patients with type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "SGLT2 inhibitors significantly decreased serum alanine levels (-7.43U/L) and improved liver function markers, suggesting a beneficial effect on liver structure and function in T2D patients. The treatment was also associated with reduced liver steatosis.", "population_specificity": "Patients with type 2 diabetes (T2D), with or without non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "At least 8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:45.446347+00:00"}
{"study_id": 103355, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on the combination of atezolizumab and trastuzumab emtansine for HER2-positive advanced breast cancer.", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:46.522323+00:00"}
{"study_id": 103356, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the clinical features and liver injury, specifically elevated alanine aminotransferase (ALT) levels, in Japanese patients with COVID-19.", "results_summary": "Elevated ALT levels were found in 12 out of 22 patients (54.5%), and liver injury was observed in 15 patients (68.2%). Liver injury was associated with higher body temperature but not with COVID-19 severity or mortality.", "population_specificity": "Japanese patients with COVID-19 (median age 47 years; 13 men, 9 women).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:47.645188+00:00"}
{"study_id": 103358, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to review current evidence and recommendations for managing HBV infection in pregnancy, including monitoring alanine transaminase levels post-birth.", "results_summary": "The study suggests monitoring alanine transaminase levels every 1 to 3 months until 6 months postpartum to detect hepatitis flare after birth and antiviral drug discontinuation.", "population_specificity": "Pregnant women with HBV infection and their neonates.", "effective_dosage": "Not specified", "study_duration": "Monitoring suggested until 6 months postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:47.845318+00:00"}
{"study_id": 103357, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze potential drug interactions between vonoprazan and tacrolimus in kidney transplant recipients.", "results_summary": "The study retrospectively analyzed 52 kidney transplant recipients switched from rabeprazole to vonoprazan, noting anticipated drug interactions due to shared CYP3A4 metabolism pathways. No specific results regarding Alanine were mentioned.", "population_specificity": "Kidney transplant recipients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "Potential drug interaction with tacrolimus due to shared CYP3A4 metabolism.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:48.037723+00:00"}
{"study_id": 103360, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of a low-carbohydrate and high-fiber diet combined with education on metabolic indicators, including serum alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease.", "results_summary": "The study found that the intervention significantly reduced serum alanine aminotransferase levels, along with improvements in body weight, body fat, and other metabolic markers, particularly in female patients.", "population_specificity": "44 patients with nonalcoholic fatty liver disease, divided by sex (male and female).", "effective_dosage": "Not specified", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:49.733878+00:00"}
{"study_id": 103361, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the risk for participants in first-in-human multiple-dose studies, including safety laboratory results related to alanine aminotransferase (ALT).", "results_summary": "The study found that subjects were not exposed to undue risk, with adverse events and laboratory value increases occurring frequently even under placebo treatment. No specific adverse effects related to alanine were highlighted.", "population_specificity": "Healthy male subjects (mean age 33.8 years, mean BMI 24.7 kg/m\u00b2).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:49.794405+00:00"}
{"study_id": 103359, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of Debio 1143 when combined with cisplatin-based chemoradiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN).", "results_summary": "The study found that the RP2D of Debio 1143 was 200 mg/day for 14 days every 3 weeks, with manageable safety and encouraging preliminary efficacy, including an 85% overall response rate and 74% progression-free survival at 24 months.", "population_specificity": "Treatment-na\u00efve patients with LA-SCCHN (stages III/IVA/IVB), all current or former smokers.", "effective_dosage": "100, 200, 300 mg/day (RP2D: 200 mg/day for 14 days every 3 weeks).", "study_duration": "Three cycles (each cycle: 3 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:51.993829+00:00"}
{"study_id": 103362, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to analyze the relationship between coagulation dysfunction and liver damage, as indicated by alanine aminotransferase (ALT) levels, in COVID-19 patients.", "results_summary": "The study found that ALT and AST levels, markers of liver damage, were positively correlated with coagulopathy in COVID-19 patients, suggesting a link between liver damage and coagulation dysfunction.", "population_specificity": "74 COVID-19 patients admitted to the First People's Hospital of Yueyang from January to March 2020.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:53.008552+00:00"}
{"study_id": 103363, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic effects and safety of stem cell therapy for chronic liver disease, including its impact on alanine aminotransferase levels.", "results_summary": "The study found that stem cell therapy had no obvious beneficial effects on alanine aminotransferase levels compared to conventional treatment. However, it improved other liver function markers like total bilirubin and albumin.", "population_specificity": "Patients with chronic liver disease, including those with acute-on-chronic liver failure (ACLF).", "effective_dosage": "Not specified for alanine aminotransferase specifically.", "study_duration": "Not specified for alanine aminotransferase specifically.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.467264+00:00"}
{"study_id": 103364, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the prevalence and impact of hepatic injury, including elevated alanine transaminase levels, in COVID-19 patients.", "results_summary": "The study found that 21% of COVID-19 patients had elevated alanine transaminase levels, indicating hepatic injury, and worse clinical outcomes were associated with hepatic injury in most cases.", "population_specificity": "Patients infected with COVID-19 (N=3046) from 13 studies.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.870490+00:00"}
{"study_id": 103366, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the correlation between serum REG I\u03b1 levels and cancer, including the role of alanine aminotransferase as a potential biomarker.", "results_summary": "The study found significantly higher serum REG I\u03b1 levels and alanine aminotransferase in cancer patients, with REG I\u03b1 identified as an independent risk factor for cancer. Higher REG I\u03b1 levels were also associated with metastasis.", "population_specificity": "130 hospitalized patients from the department of internal medicine in Zhongda Hospital Southeast University, divided into cancer and noncancer groups.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:55.558003+00:00"}
{"study_id": 103365, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether vitamin D supplementation has beneficial effects on alanine aminotransferase (ALT) and other metabolic markers in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that vitamin D supplementation marginally reduced ALT levels (-0.18; 95%CI: -0.39, 0.04) and significantly improved glycemic control and insulin sensitivity, but did not significantly affect AST, TC, HDL-C, or LDL-C levels.", "population_specificity": "544 subjects with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:56.205813+00:00"}
{"study_id": 103368, "supplement_id": 863, "safety_score": "100", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to examine the effects of \u03b4-tocotrienol supplementation on biochemical markers of hepatocellular injury and steatosis, including alanine transaminase (ALT), in patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "\u03b4-tocotrienol significantly reduced ALT levels (-8.86 [-11.5, -6.2]; p < 0.001) and other markers of liver injury and steatosis compared to placebo, with no reported adverse events.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "300 mg twice daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:58.091697+00:00"}
{"study_id": 103367, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of duodenal mucosal resurfacing (DMR) in improving glycemic indices and metabolic outcomes, including alanine transaminase levels, in patients with type 2 diabetes.", "results_summary": "The study found that DMR was feasible and safe, with reductions in glycated hemoglobin, weight, fasting plasma glucose, and alanine transaminase levels observed at various follow-up points. Patients with longer duodenal segment ablation showed greater beneficial effects, though the insulin-sensitizing mechanism remains unclear.", "population_specificity": "Humans with type 2 diabetes (T2D).", "effective_dosage": "Not Assessed", "study_duration": "Different follow-up time-points (specific duration not mentioned).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:58.451994+00:00"}
{"study_id": 103369, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To establish expert recommendations on treatment initiation for chronic hepatitis B (CHB) based on alanine aminotransferase (ALT) levels, HBV DNA levels, cirrhosis, and HCC risk scores in East Asia.", "results_summary": "Anti-viral therapy is recommended for CHB patients with specific criteria, including elevated ALT and HBV DNA levels, fibrosis, cirrhosis, or HCC risk factors. Patients with cirrhosis and/or HCC should be treated regardless of ALT levels if HBV DNA is detectable.", "population_specificity": "Chronic hepatitis B patients in East Asia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:59.954871+00:00"}
{"study_id": 103371, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify associations between COVID-19 disease severity and various clinical, laboratory, and radiological characteristics, including elevated alanine aminotransferase (ALT).", "results_summary": "Elevated alanine aminotransferase (ALT) was strongly associated with more severe COVID-19 disease, with prevalence increasing by 30-73% from mild/early to moderate/severe disease.", "population_specificity": "Hospitalized patients with confirmed COVID-19 (n = 91,621 across 86 studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:02.552648+00:00"}
{"study_id": 103370, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the safety and pharmacokinetics of combining crizotinib (a c-MET inhibitor) with enzalutamide (an AR antagonist) in castration-resistant prostate cancer (CRPC) patients.", "results_summary": "The study found a clinically significant 74% decrease in systemic crizotinib exposure when combined with enzalutamide, leading to the conclusion that further investigation of this combination is not planned.", "population_specificity": "Patients with castration-resistant prostate cancer (CRPC).", "effective_dosage": "Crizotinib (250 mg daily, 200 mg twice a day, and 250 mg twice a day) with enzalutamide (160 mg daily).", "study_duration": "Not specified in the abstract.", "interactions": "Significant pharmacokinetic interaction between enzalutamide and crizotinib, reducing crizotinib exposure.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:03.769380+00:00"}
{"study_id": 103376, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specifically address the study of Alanine.", "results_summary": "The abstract does not report findings related to Alanine.", "population_specificity": "Not specified for Alanine.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:03.817678+00:00"}
{"study_id": 103374, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study compared clinical and laboratory features between COVID-19 and influenza A in children, including alanine aminotransferase levels.", "results_summary": "The study found that alanine aminotransferase levels in children with COVID-19 were lower than in influenza A inpatients but higher than in outpatients.", "population_specificity": "Hospitalized children with COVID-19 (n=23) and age- and sex-matched influenza A patients (inpatients n=69, outpatients n=69).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:04.106999+00:00"}
{"study_id": 103373, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the association between elevated alanine aminotransferase (ALT) levels and poor clinical outcomes in hospitalized COVID-19 patients.", "results_summary": "Elevated ALT levels were independently associated with a higher risk of poor outcomes (OR: 1.71, 95% CI: 1.32-2.20; p<0.00001), suggesting a link between ALT and COVID-19 severity. The study did not assess ALT as a therapeutic intervention but as a biomarker of disease progression.", "population_specificity": "Hospitalized COVID-19 patients (10,491 participants across 32 studies).", "effective_dosage": "Not applicable (ALT was measured as a biomarker, not administered).", "study_duration": "Not applicable (observational study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:04.287625+00:00"}
{"study_id": 103372, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the incidence and factors associated with clinical outcomes in a multiethnic North American cohort of adults with chronic HBV infection not on antiviral therapy at enrollment.", "results_summary": "The study found a low incidence of adverse outcomes in a closely monitored cohort of predominantly inactive chronic HBV patients without cirrhosis, highlighting the benefits of HBsAg loss and the importance of early diagnosis and treatment.", "population_specificity": "Multiethnic North American adults with chronic HBV infection, not receiving antiviral therapy, and without a history of decompensation, HCC, or liver transplantation.", "effective_dosage": "Not mentioned", "study_duration": "6,641 person-years follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:04.470857+00:00"}
{"study_id": 103375, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinical characteristics and outcomes of COVID-19 patients co-infected with HBV, including the impact on liver injury markers like alanine aminotransferase (ALT).", "results_summary": "The study found that COVID-19 patients with HBV co-infection had significantly higher ALT levels, indicating greater liver injury, compared to those without HBV. Age and CRP levels were identified as independent risk factors for severe outcomes in co-infected patients.", "population_specificity": "COVID-19 patients with and without chronic HBV infection from seven hospitals.", "effective_dosage": "Not specified", "study_duration": "Data collected from January 20 to March 20, 2020 (2 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:06.568959+00:00"}
{"study_id": 103377, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, efficacy, and pharmacokinetics of almonertinib (a third-generation EGFR TKI) in patients with locally advanced or metastatic EGFR mutation-positive NSCLC who had progressed after previous EGFR TKI therapy.", "results_summary": "Almonertinib demonstrated a favorable safety profile with manageable adverse events (e.g., increased blood creatine phosphokinase and alanine aminotransferase) and showed efficacy, with an objective response rate of 52% and disease control rate of 92% in patients with the EGFR T790M mutation. Median progression-free survival was 11.0 months.", "population_specificity": "Patients with locally advanced or metastatic EGFR mutation-positive NSCLC who had progressed after previous EGFR TKI therapy.", "effective_dosage": "55, 110, 220, and 260 mg once daily (260 mg was not further evaluated in the dose-expansion phase).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:10.176887+00:00"}
{"study_id": 103379, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on the efficacy of Tocilizumab (TCZ) in treating COVID-19-related hyperinflammation.", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Patients with severe COVID-19 in a single-center French hospital.", "effective_dosage": "Not mentioned (study does not involve Alanine).", "study_duration": "Not mentioned (study does not involve Alanine).", "interactions": "None mentioned (study does not involve Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:11.249595+00:00"}
{"study_id": 103383, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To determine whether early, short-term, low-dose glucocorticoid treatment prevents the progression of severe acute exacerbation of chronic hepatitis B to liver failure.", "results_summary": "Serum alanine transaminase levels were significantly lower in the hormone group than in the control group at 3 days and 1 week after treatment. The incidence of liver failure and duration of hospitalization were significantly lower in the hormone group.", "population_specificity": "Patients with severe acute exacerbation of chronic hepatitis B.", "effective_dosage": "Low-dose glucocorticoid (specific dosage not detailed).", "study_duration": "3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:12.932649+00:00"}
{"study_id": 103381, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy of sour tea supplementation (containing Alanine) in improving liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with NAFLD.", "results_summary": "Sour tea supplementation significantly reduced serum triglyceride, ALT, AST, systolic and diastolic blood pressure, and increased total antioxidant capacity, but did not affect anthropometric measures or cholesterol levels.", "population_specificity": "70 patients with nonalcoholic fatty liver disease (NAFLD), with 61 completing the study.", "effective_dosage": "450 mg capsule daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:13.174893+00:00"}
{"study_id": 103380, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the long-term safety and efficacy of teriflunomide, including its effects on alanine aminotransferase levels, in patients with relapsing forms of multiple sclerosis (RMS).", "results_summary": "The study found that alanine aminotransferase increases occurred more frequently in the placebo/teriflunomide 14 mg group (11.2%) compared to other groups (3.0%-5.2%). Overall, the safety profile was consistent with the core trial, and efficacy was maintained over time.", "population_specificity": "Patients with relapsing forms of multiple sclerosis (RMS).", "effective_dosage": "Teriflunomide 14 mg (daily).", "study_duration": "Median exposure of 4.25 years (maximum 6.3 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:13.179099+00:00"}
{"study_id": 103378, "supplement_id": 863, "safety_score": "65", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy, recommended phase 2 dose, and toxicities of lorvotuzumab mertansine, including its impact on alanine aminotransferase levels.", "results_summary": "The study reported increased alanine aminotransferase levels in some patients, indicating potential liver toxicity, but non-dose-limiting toxicities were rare. Limited efficacy was observed, with only one partial response in rhabdomyosarcoma and one delayed complete response in synovial sarcoma.", "population_specificity": "Pediatric and young adult patients (ages 2.8-29.9 years) with relapsed or progressive Wilms tumor, rhabdomyosarcoma, neuroblastoma, synovial sarcoma, MPNST, or pleuropulmonary blastoma.", "effective_dosage": "110 mg/m\u00b2", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:13.352905+00:00"}
{"study_id": 103382, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of a modified HTK solution (HTK-N) containing alanine in attenuating cold storage injury in organ transplantation.", "results_summary": "HTK-N, which includes alanine, demonstrated superior antioxidative capacity and improved tolerance to cold storage compared to standard HTK, particularly in liver and heart graft preservation. In vivo and in vitro studies supported its potential advantages, though further clinical trials are needed.", "population_specificity": "Animal models (liver, kidney, pancreas, small bowel, heart, and lung transplantation) and in vitro studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:13.469687+00:00"}
{"study_id": 103384, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on pediatric Ebola virus disease (EVD) epidemiology, clinical management, and psychosocial considerations.", "results_summary": "The study does not discuss Alanine; it reviews pediatric EVD outbreaks, clinical manifestations, and management challenges.", "population_specificity": "Pediatric cases of Ebola virus disease (EVD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:15.346143+00:00"}
{"study_id": 103385, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify early predictive factors, including elevated alanine aminotransferase (ALT), for the progression of COVID-19 patients to severe pneumonia.", "results_summary": "Elevated ALT was identified as a significant risk factor (OR = 6.87) for progression to severe pneumonia in COVID-19 patients, alongside chronic comorbidities and high hs-CRP levels.", "population_specificity": "Adult inpatients (\u226518 years old) with laboratory-confirmed early-stage COVID-19 from two hospitals in China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:18.823298+00:00"}
{"study_id": 103386, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate changes in cardiometabolic outcomes, including alanine aminotransferase levels, during a lifestyle intervention in obese women.", "results_summary": "The study found a significant decrease in alanine aminotransferase (-8.0%) in women who achieved weight loss, indicating improved liver function, though irisin levels remained unchanged.", "population_specificity": "111 obese women aged 36.73 \u00b1 7.2 years.", "effective_dosage": "Not specified", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:20.208090+00:00"}
{"study_id": 103391, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to identify laboratory markers, including alanine aminotransferase, associated with severe COVID-19 outcomes.", "results_summary": "The study found elevated alanine aminotransferase as a marker of tissue injury in hospitalized COVID-19 patients, suggesting its potential role in predicting unfavorable outcomes.", "population_specificity": "Hospitalized COVID-19 patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.596492+00:00"}
{"study_id": 103387, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to determine the effect of vitamin D supplementation on obesity and related metabolic abnormalities among obese Sri Lankan children with vitamin D deficiency.", "results_summary": "The study found that a strict dietary and physical activity regimen improved some anthropometric, body composition, and metabolic profiles, and high-dose vitamin D enhanced these improvements, particularly in vitamin D levels and ALT.", "population_specificity": "Obese Sri Lankan children with vitamin D deficiency (n=96).", "effective_dosage": "Not specified (referred to as \"high dose vitamin D\").", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.877075+00:00"}
{"study_id": 103389, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of probiotic and prebiotic supplementation on metabolic parameters, liver enzymes (including alanine aminotransferase, ALT), and inflammation in NAFLD patients.", "results_summary": "Probiotic supplementation significantly reduced ALT, AST, GGT, and triglyceride levels compared to the control group. Prebiotic supplementation also showed significant improvements in lipid profiles and liver enzymes, including ALT.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified for alanine (ALT was measured as an outcome, not supplemented).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:22.385864+00:00"}
{"study_id": 103388, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the safety of methotrexate versus secukinumab in psoriasis patients with metabolic syndrome, focusing on liver enzyme levels, including alanine aminotransferase (ALT).", "results_summary": "The study found that methotrexate significantly increased liver enzyme levels (including ALT) at 6 and 12 months, leading to drug withdrawal in some patients, while secukinumab had no such effect. No significant changes in other metabolic parameters were observed.", "population_specificity": "Psoriasis patients with metabolic syndrome (110 male, 20 female).", "effective_dosage": "Methotrexate: 15 mg weekly; secukinumab: standard dose.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:22.951749+00:00"}
{"study_id": 103390, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to discuss the specificity of transaminases, particularly alanine aminotransferase, in detecting drug-induced liver injury (DILI) and explore future perspectives for their use in DILI risk assessment.", "results_summary": "The study found that transaminase activity in the blood can be altered by factors unrelated to liver toxicity, such as nutritional or hormonal changes, and certain drugs may cause pharmacology-related elevation without indicating DILI. The authors suggest using additional biomarkers for more accurate DILI assessment.", "population_specificity": "Not specified (general discussion of transaminases in clinical and non-clinical contexts)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "Mentioned interactions with drugs like \u03b1-glucosidase inhibitors and fibrates, which may slightly increase transaminase activity without causing liver injury.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:23.356579+00:00"}
{"study_id": 103392, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether specific genetic polymorphisms, including those related to hepatic lipid metabolism, are associated with an increased risk of IFN\u03b2-induced liver toxicity, as measured by elevated ALT and AST levels.", "results_summary": "The study found that the PNPLA3 variant was significantly associated with IFN\u03b2-induced liver toxicity, while other examined polymorphisms showed no significant association. The results suggest that genetic screening for PNPLA3 could help identify patients at higher risk of liver toxicity from IFN\u03b2 therapy.", "population_specificity": "113 multiple sclerosis (MS) patients treated with IFN\u03b2.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:24.835037+00:00"}
{"study_id": 103393, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of probiotics on serum alanine aminotransferase (ALT) levels in pediatric patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Probiotic therapy significantly reduced ALT levels in pediatric NAFLD patients compared to placebo, with no significant differences observed in secondary outcomes like aspartate aminotransferase, BMI, triglycerides, waist circumference, or liver steatosis.", "population_specificity": "Pediatric patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Lactobacillus rhamnosus for 8 weeks; Bifidobacterium+Lactobacillus for 12 weeks (specific dosage not mentioned).", "study_duration": "8-12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:27.011157+00:00"}
{"study_id": 103394, "supplement_id": 863, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the feasibility and safety of a Chinese herbal formula as a therapeutic option for chronic HBV infection in patients with persistently normal alanine aminotransferase levels.", "results_summary": "The Chinese herbal formula showed higher rates of HBV DNA reduction, HBeAg clearance, and seroconversion compared to placebo, with relatively safe outcomes. Alanine aminotransferase elevation at weeks 12 and 24 was a predictor of HBeAg clearance.", "population_specificity": "HBeAg-positive chronic hepatitis B patients (30-65 years old) with persistently normal alanine aminotransferase levels.", "effective_dosage": "Not specified", "study_duration": "96 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:28.586032+00:00"}
{"study_id": 103396, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the stability of biochemical analytes, including Alanine aminotransferase, during pre-analytical processes.", "results_summary": "The study reviewed 20 articles and found that the stability of analytes like Alanine aminotransferase varied between 2 hours and 1 week depending on sample type and storage conditions.", "population_specificity": "Not specified (general clinical laboratory context)", "effective_dosage": "Not available", "study_duration": "Not applicable (literature review)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:28.932428+00:00"}
{"study_id": 103395, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the effectiveness of combining traditional Chinese medicine (TCM) with Western medicine (pegylated interferon and ribavirin) in treating hepatitis C, particularly focusing on liver function indicators like alanine aminotransferase (ALT).", "results_summary": "The combination therapy significantly improved HCV-RNA negative rates and liver function indicators (ALT, AST, ALB) compared to monotherapy, though it did not affect TB or GGT levels. Liver fibrosis parameters were also more effectively reduced with the combination therapy.", "population_specificity": "Patients with hepatitis C.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:29.799070+00:00"}
{"study_id": 103397, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The study examined the effect of dulaglutide (not Alanine) on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Dulaglutide significantly reduced liver fat content (-3.5% absolute change, -26.4% relative change) and improved GGT levels, with non-significant reductions in AST, ALT, pancreatic fat content, and liver stiffness.", "population_specificity": "Adults with type 2 diabetes and NAFLD (MRI-derived liver fat \u22656.0%).", "effective_dosage": "Once-weekly dulaglutide (specific dosage not mentioned in abstract).", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:30.920323+00:00"}
{"study_id": 103399, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of dietary cholesterol in statin-related hepatotoxicity, using hamsters as a model.", "results_summary": "The study found that rosuvastatin caused fatal liver damage in high-cholesterol diet-fed wild-type hamsters, suggesting dietary cholesterol significantly contributes to statin-related hepatotoxicity.", "population_specificity": "Wild-type and LDLR knockout hamsters fed a high-cholesterol diet.", "effective_dosage": "10 mg/kg of rosuvastatin.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:31.078601+00:00"}
{"study_id": 103398, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to determine the effects of bardoxolone methyl (an Nrf2 activator) on kidney function and liver enzyme levels, particularly alanine aminotransferase (ALT), in patients with type 2 diabetes and chronic kidney disease.", "results_summary": "Bardoxolone methyl improved kidney function but increased ALT, AST, and gamma glutamyl transferase levels, which were reversible and likely related to pharmacological induction rather than hepatotoxicity. Animal and cell studies supported that these increases were due to Nrf2 activation.", "population_specificity": "2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.", "effective_dosage": "Not specified in the abstract.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:32.516836+00:00"}
{"study_id": 103400, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of synbiotic supplementation (B. coagulans plus inulin) on reducing hepatic steatosis and inflammation in patients with NAFLD.", "results_summary": "Synbiotic supplementation significantly reduced serum alanine aminotransferase, \u03b3 glutamine transaminase, tumor necrosis factor-\u03b1, nuclear factor-\u03baB activity, and hepatic steatosis compared to placebo. The intervention showed no significant effects on related cardiovascular risk factors.", "population_specificity": "Fifty-three patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:32.637676+00:00"}
{"study_id": 103402, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of dapagliflozin-induced glucosuria on endogenous glucose production (EGP) in non-diabetic individuals, comparing those with residual native kidneys to nephrectomised individuals.", "results_summary": "Dapagliflozin induced greater glucosuria in individuals with residual native kidneys compared to nephrectomised individuals. EGP declined in both groups after dapagliflozin administration, but the compensatory hepatic response was attenuated in nephrectomised individuals, suggesting a renal-hepatic axis mechanism.", "population_specificity": "Non-diabetic renal transplant patients (30-65 years old, BMI 25-35 kg/m\u00b2), including ten with residual native kidneys and ten with bilateral nephrectomy.", "effective_dosage": "Single dose of dapagliflozin (specific amount not stated).", "study_duration": "6-hour study period.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:38.089236+00:00"}
{"study_id": 103401, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the efficacy and safety of selpercatinib in patients with medullary thyroid cancer, with or without prior treatment with vandetanib or cabozantinib.", "results_summary": "The study found that selpercatinib demonstrated durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer, regardless of prior treatment with vandetanib or cabozantinib.", "population_specificity": "Patients with medullary thyroid cancer, with and without previous vandetanib or cabozantinib treatment.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:38.477569+00:00"}
{"study_id": 103403, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess changes in clinical phenotype and identify determinants of outcome in children with chronic HBV infection, focusing on immune status and ethnicity.", "results_summary": "The study found that ethnicity and immune status phenotype were key determinants of seroconversion to hepatitis B e antibodies (SCHBe), with Asian origin reducing the probability of SCHBe compared to other ethnicities. Immune-active patients had higher SCHBe rates (28%) than immune-tolerant patients (11%).", "population_specificity": "Foreign-born children with chronic HBV infection (median age 4.7 years) followed in Italian tertiary care centers.", "effective_dosage": "Not mentioned", "study_duration": "Median follow-up of 53 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:40.609291+00:00"}
{"study_id": 105544, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the reliability of LecT-Hepa (a serological glycomarker) with FibroScan for evaluating liver fibrosis, particularly focusing on the effects of increased alanine aminotransferase (ALT) activities.", "results_summary": "LecT-Hepa showed comparable performance to FibroScan in detecting cirrhosis, with similar sensitivity and specificity. Unlike FibroScan, LecT-Hepa's results were unaffected by ALT levels, indicating robustness against inflammation.", "population_specificity": "Hepatitis B virus-infected patients.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.206250+00:00"}
{"study_id": 105546, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of alanine residue substitutions in altering T cell responses to K17 pathogenic peptides in psoriasis.", "results_summary": "Alanine substitutions at critical TCR contact positions abolished T cell proliferation and IFN-\u03b3 production induced by K17 pathogenic peptides, suggesting potential therapeutic applications. The study also found that K17-specific antisense ODNs and RNAi suppressed K17 expression, correlating with clinical improvement in psoriasis.", "population_specificity": "Patients with psoriasis, particularly those with HLA DRB1*04 and/or *07 positive status.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.285820+00:00"}
{"study_id": 105550, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of IL28B genotype on HCV recurrence, allograft histology, SVR rate, and survival after liver transplantation, including its association with alanine aminotransferase levels.", "results_summary": "Recipient IL28B CC genotype was associated with lower alanine aminotransferase levels and viral load at recurrence, while donor CC genotype was linked to higher inflammation and fibrosis. Both recipient and donor CC genotypes favored SVR, with a 90% rate when combined.", "population_specificity": "Liver transplant recipients with HCV.", "effective_dosage": "Not specified", "study_duration": "Follow-up of 5.5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.758119+00:00"}
{"study_id": 105545, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the safety and tolerance of a soybean/MCT/olive/fish oil emulsion in intestinal failure patients on long-term parenteral nutrition, not specifically focused on Alanine.", "results_summary": "The study found that the soybean/MCT/olive/fish oil emulsion was safe and well tolerated, with lower ALT, AST, and bilirubin levels compared to the control. It also improved fatty acid profiles and increased serum \u03b1-tocopherol concentrations.", "population_specificity": "73 patients with stable intestinal failure requiring long-term parenteral nutrition.", "effective_dosage": "Not specified for Alanine.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.821012+00:00"}
{"study_id": 105549, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the incidence of tuberculosis reactivation and hepatotoxicity in patients treated with golimumab, with a focus on alanine aminotransferase elevations during anti-TB therapy.", "results_summary": "The study found that alanine aminotransferase elevations occurred more frequently in patients treated for latent TB infection, but these were mostly mild. No active TB cases developed in patients treated with isoniazid, suggesting effective latent TB management.", "population_specificity": "Patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving golimumab in TB-endemic regions.", "effective_dosage": "Not specified", "study_duration": "Up to 52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:50.055621+00:00"}
{"study_id": 105548, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety and efficacy of TJ-15 plus TJ-17 (herbal formulas) for treating the Dampness-Heat pattern of atopic dermatitis, not specifically Alanine.", "results_summary": "The study found that both TJ-15 plus TJ-17 and TJ-15 alone improved SCORAD and EASI scores, though differences were not statistically significant. No adverse events or abnormalities in liver/kidney function tests were reported.", "population_specificity": "Patients with the Dampness-Heat pattern of atopic dermatitis (n=19 completed).", "effective_dosage": "Orally administered 3 times daily (specific dosage not detailed).", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:50.303590+00:00"}
{"study_id": 105551, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the safety and pharmacokinetics of edaravone administered via single or successive intravenous infusions in healthy Chinese volunteers.", "results_summary": "The study found that edaravone was safe and well tolerated, with mild and reversible laboratory abnormalities (e.g., increased alanine transaminase). Pharmacokinetic parameters (AUC(\u03c4) and C(max)) showed linear increases with dose.", "population_specificity": "Healthy Chinese volunteers (15 males and 15 females).", "effective_dosage": "20, 30, and 60 mg single doses; 30 mg twice daily for 5 days in the repeated-dose group.", "study_duration": "Single dose (30-minute infusion) or 5 days (repeated dosing).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:50.454663+00:00"}
{"study_id": 105547, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of LY2605541 (a novel insulin analog) versus insulin glargine (GL) on fasting blood glucose, glycemic variability, weight changes, and hypoglycemia rates in patients with type 2 diabetes.", "results_summary": "LY2605541 showed comparable glucose control and total hypoglycemia rates to GL but reduced intraday blood glucose variability and nocturnal hypoglycemia while promoting weight loss. Alanine aminotransferase and aspartate aminotransferase levels were higher with LY2605541 but remained within normal range.", "population_specificity": "Patients with type 2 diabetes (A1C \u2264 10.5%) taking metformin and/or sulfonylurea with GL or NPH insulin once daily.", "effective_dosage": "Once daily in the morning (specific dosage not provided).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:50.724335+00:00"}
{"study_id": 105557, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "To investigate if levetiracetam (LEV) prevents relapse after detoxification compared with placebo in patients with alcohol dependence, with secondary outcomes including safety markers like serum alanine aminotransferase.", "results_summary": "The study found no significant difference in relapse rates or time to relapse between LEV and placebo groups, though fewer LEV-treated patients terminated treatment early. Safety and tolerability were similar between groups.", "population_specificity": "Patients with alcohol dependence after detoxification.", "effective_dosage": "Fixed-dose schedule (specific dosage not mentioned in abstract).", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:58.035359+00:00"}
{"study_id": 105554, "supplement_id": 863, "safety_score": "70", "efficacy_score": 45, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy and safety of lesogaberan (AZD3355), a GABA B-type receptor agonist, as an add-on therapy for GERD patients partially responsive to PPI therapy.", "results_summary": "Lesogaberan showed a marginally superior response compared to placebo, with the 240 mg dose achieving statistical significance. However, the absolute improvement was low, and six patients developed reversible elevated alanine transaminase levels.", "population_specificity": "GERD patients partially responsive to PPI therapy.", "effective_dosage": "60, 120, 180, or 240 mg twice daily.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:58.116099+00:00"}
{"study_id": 105558, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to develop a simple model using routine laboratory variables, including alanine aminotransferase, to predict liver fibrosis and cirrhosis in chronic HBV-infected patients.", "results_summary": "The study found that alanine aminotransferase was one of the variables analyzed, but only platelet count and globulin were independently correlated with fibrosis stages. The newly developed GP model showed the highest correlation coefficient among the tested models for predicting fibrosis and cirrhosis.", "population_specificity": "Chronic HBV-infected patients who underwent liver biopsy (n=114).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:59.565590+00:00"}
{"study_id": 105552, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the immunological effectiveness and safety of a DNA vaccine against HBV, with a focus on its impact on alanine aminotransferase (ALT) levels and HBV-specific T-cell responses in chronic hepatitis B patients.", "results_summary": "The study found that the DNA vaccine significantly elevated HBV-specific IFN-\u03b3-secreting T-cell counts in patients with ALT levels 1-2 times ULN (Group01). In Group02, the combined therapy (LAM+DNA vaccine) showed higher HBV DNA suppression, lower virological breakthrough rates, and higher positive T-cell response rates compared to LAM monotherapy.", "population_specificity": "HBeAg-positive patients with chronic hepatitis B (CHB), divided into those with ALT 1-2 times ULN (Group01) and those with ALT >2 times ULN (Group02).", "effective_dosage": "Not specified", "study_duration": "Final injection at week 36, follow-up until week 60", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:59.785402+00:00"}
{"study_id": 105553, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to confirm the efficacy and safety of glycyrrhizin in reducing ALT levels and improving necro-inflammation in chronic hepatitis C patients who did not respond to interferon + ribavirin therapy.", "results_summary": "Glycyrrhizin significantly reduced ALT levels by \u226550% after 12 weeks (28.7% for 5\u00d7/week, 29.0% for 3\u00d7/week vs. 7.0% for placebo) and improved necro-inflammation after 52 weeks (44.9% for 5\u00d7/week, 46.0% for 3\u00d7/week). The treatment was generally well tolerated.", "population_specificity": "Chronic hepatitis C patients who were non-responders to interferon + ribavirin therapy.", "effective_dosage": "Intravenous glycyrrhizin 5\u00d7/week or 3\u00d7/week.", "study_duration": "12 weeks (double-blind phase) followed by 40 weeks (open phase).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:59.878513+00:00"}
{"study_id": 105555, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify specific inhibitors of proMMP-9-cell binding by characterizing B-CLL cell interaction with the isolated PEX9 domain and evaluating the role of alanine-mutated peptides in this process.", "results_summary": "The study found that peptide P3 (containing a specific sequence in the B4 blade of PEX9) and its smaller versions inhibited B-CLL cell adhesion to GST-PEX9 and proMMP-9, with IC50 values of 138 and 279 \u03bcm, respectively. Mutating aspartate residues to alanine rendered the peptides inactive, and the P3 sequence also inhibited B-CLL cell transendothelial migration and intracellular survival signals.", "population_specificity": "B chronic lymphocytic leukemia (B-CLL) cells from 20 primary samples.", "effective_dosage": "Not specified (peptide concentrations tested in functional assays).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.210409+00:00"}
{"study_id": 105559, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of traditional Chinese medicine (TCM), including herbs like Hawthorn Fruit, in treating nonalcoholic fatty liver disease (NAFLD), with a focus on outcomes such as normalization of alanine aminotransferase (ALT) levels.", "results_summary": "TCM showed a better effect than western medicines in normalizing ALT levels and reducing radiological steatosis in NAFLD patients. Hawthorn Fruit was the most frequently used herb in TCM formulations for NAFLD treatment.", "population_specificity": "5,904 patients from 62 RCTs (meta-analysis) and 25,661 patients from 419 clinical studies (TCM formulation analysis) with NAFLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.443983+00:00"}
{"study_id": 105556, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in patients with hepatic metastases from neuroendocrine tumors (NETs), not specifically studying Alanine.", "results_summary": "The study found a mean 12% decrease in tumor size and a 56% decrease in tumor enhancement at 1-month follow-up, with a targeted lesion objective response rate of 78% by EASL criteria. However, there was a high incidence of bilomas (54%) and liver abscesses, leading to trial interruption.", "population_specificity": "13 patients with hepatic metastases from neuroendocrine tumors (mean age 65 years, ECOG status 0/1).", "effective_dosage": "Up to four DEB-TACE sessions (100-300 \u03bcm beads loaded with \u2264100 mg doxorubicin) within 6 months.", "study_duration": "Up to 6 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.582052+00:00"}
{"study_id": 105560, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and antitumoral efficacy of a modified adenovirus vector (Ad5-477dlTAYT(A20)) targeting \u03b1(v)\u03b2(6) integrin in carcinomas, with a focus on reducing hepatotoxicity and improving tumor transduction.", "results_summary": "The modified vector showed improved safety (reduced hepatotoxicity, thrombocytopenia, and inflammation) compared to the wild-type virus, but despite efficient tumor transduction, it did not enhance antitumoral efficacy due to poor intratumoral dissemination.", "population_specificity": "Human carcinomas (in vitro/in vivo study, not specified if human or animal model for some aspects).", "effective_dosage": "2\u00d710^10 to 4\u00d710^10 viral particles.", "study_duration": "Observations at 1, 24, and 96 hours post-delivery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:08.266159+00:00"}
{"study_id": 105561, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to test whether ursodeoxycholic acid reduces pruritus in women with intrahepatic cholestasis of pregnancy and whether early term delivery affects caesarean section rates, with alanine transaminase levels as a biochemical marker.", "results_summary": "Ursodeoxycholic acid reduced itching by -16 mm (95% CI -27 to -6 mm), though the effect was smaller than the clinically meaningful 30 mm threshold. Early term delivery did not significantly increase caesarean section rates (23% vs. 33%).", "population_specificity": "Pregnant women with intrahepatic cholestasis (pruritus and raised serum bile acids or alanine transaminase >100 IU/L) after 24 weeks' gestation.", "effective_dosage": "500 mg ursodeoxycholic acid twice daily (adjusted as needed).", "study_duration": "Until delivery (variable, depending on gestational age at recruitment).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:08.346712+00:00"}
{"study_id": 105562, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers investigated whether reduced hepatic inflammation (measured via alanine aminotransferase levels and Ishak HAI) was associated with clinical benefits, fibrosis progression, and virological suppression in hepatitis C patients.", "results_summary": "Reduced hepatic inflammation was linked to virological suppression during lead-in therapy, decreased fibrosis progression, and fewer clinical outcomes, independent of randomized treatment. The association persisted at follow-up periods of 1.5 and 3.5 years.", "population_specificity": "834 hepatitis C patients with advanced fibrosis or cirrhosis, previously nonresponsive to interferon therapy.", "effective_dosage": "Not specified (full-dose peginterferon/ribavirin used in lead-in therapy).", "study_duration": "1.5 to 3.5 years post-randomization (median follow-up of 6 years).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:08.872161+00:00"}
{"study_id": 105567, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study evaluated the safety, efficacy, and tolerability of elinogrel, a P2Y(12) inhibitor, in patients undergoing nonurgent percutaneous coronary intervention, but did not specifically focus on Alanine.", "results_summary": "The study found increased bleeding and transaminase elevation (including alanine transferase) with elinogrel compared to clopidogrel, but no significant differences in efficacy endpoints or cases of severe adverse events like liver failure.", "population_specificity": "Patients undergoing nonurgent percutaneous coronary intervention.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:09.382976+00:00"}
{"study_id": 105565, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative chronic hepatitis B patients, including the role of alanine aminotransferase levels as a marker of response.", "results_summary": "Among initial responders (19 patients), 63% sustained their response through long-term follow-up, with an overall 19% combined response rate. A marked decrease in serum HBsAg levels was observed, leading to HBsAg clearance in 26% of initial responders.", "population_specificity": "HBeAg-negative chronic hepatitis B patients.", "effective_dosage": "PEG-IFN \u03b1-2a (180 \u03bcg weekly) \u00b1 ribavirin (1000-1200 mg daily).", "study_duration": "48 weeks of treatment, with a mean follow-up of 2.1 \u00b1 0.2 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:10.000596+00:00"}
{"study_id": 105566, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the biochemical and virological effects of discontinuing long-term nucleos(t)ide analogue therapy (adefovir dipivoxil) in HBeAg-negative patients with chronic hepatitis B, focusing on alanine aminotransferase (ALT) levels and HBsAg clearance.", "results_summary": "After discontinuing therapy, 55% of patients achieved sustained response (HBV DNA <2000 IU/L, normal ALT), with 39% clearing HBsAg. Higher pretreatment and end-of-treatment ALT levels, no prior interferon treatment, and lower HBsAg levels at end-of-treatment were associated with HBsAg clearance.", "population_specificity": "HBeAg-negative patients with chronic hepatitis B, undetectable serum HBV DNA, and normal aminotransferase levels after 4-5 years of adefovir dipivoxil treatment.", "effective_dosage": "Not specified (long-term adefovir dipivoxil therapy).", "study_duration": "4-5 years of treatment, followed by 5.5 years of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:11.603994+00:00"}
{"study_id": 105568, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of entecavir (ETV) monotherapy versus a combination of ETV and tenofovir disoproxil fumarate (TDF) in treating chronic hepatitis B (CHB).", "results_summary": "The study found comparable antiviral efficacy between ETV monotherapy and the combination therapy, with a slight advantage for combination therapy in HBeAg-positive patients with high baseline HBV DNA levels. Alanine aminotransferase normalization was higher in the ETV monotherapy group.", "population_specificity": "Nucleos(t)ide-na\u00efve patients with chronic hepatitis B (HBeAg-positive or HBeAg-negative).", "effective_dosage": "ETV 0.5 mg daily; combination therapy included ETV 0.5 mg and TDF 300 mg daily.", "study_duration": "100 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:17.829149+00:00"}
{"study_id": 105570, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the influence of HBV coinfection on immunological, virological, and clinical responses to lamivudine-based cART, including effects on alanine aminotransferase levels.", "results_summary": "HBV serostatus was associated with different alanine aminotransferase levels during follow-up, but hepatitis and hyperbilirubinemia rates were not significantly different. The study did not focus on alanine as a supplement but rather as a biomarker (alanine aminotransferase).", "population_specificity": "Chinese patients (aged 18\u201365 years, both sexes) with HIV, including those with HBV coinfection.", "effective_dosage": "Not specified (study focused on lamivudine-based cART, not alanine supplementation).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.268959+00:00"}
{"study_id": 105572, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to explore oxymatrine's antiviral mechanism by studying its effect on HBV-specific CTL surface PD-1 expression in CHB patients.", "results_summary": "Oxymatrine significantly reduced HBV-specific CTL surface PD-1 expression, increased HBV-specific CTL levels, and improved HBV DNA and HBeAg clearance rates compared to the control group.", "population_specificity": "65 CHB patients with HBV DNA \u226510\u2074 copies/ml, positive HBeAg, HLA-A2 positive, and ALT >2x ULN.", "effective_dosage": "600 mg intravenous infusion once daily for one month, followed by 200 mg oral capsule three times daily.", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.631727+00:00"}
{"study_id": 105569, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the clinical effects and immune response in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or adefovir dipivoxil (ADV), including the role of alanine aminotransferase (ALT) as a biomarker.", "results_summary": "The study found significant decreases in serum ALT, AST, and HBV DNA levels in treated patients, indicating improved liver function. Treg profiles were significantly altered after 96 weeks of therapy, suggesting a role in immune regulation.", "population_specificity": "42 patients diagnosed with chronic hepatitis B (CHB).", "effective_dosage": "Not specified for Alanine (ALT was measured as a biomarker, not administered).", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.752103+00:00"}
{"study_id": 105571, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study evaluated the efficacy and adverse events of neoadjuvant chemotherapy (irinotecan and nedaplatin) in patients with cervical squamous cell carcinoma, not specifically Alanine.", "results_summary": "The study found a 75.8% response rate to the chemotherapy regimen, with grade 3 or 4 hematological toxicities (e.g., neutropenia, leukopenia) and minor non-hematologic toxicities. Alanine aminotransferase elevation was noted in 1.5% of cases.", "population_specificity": "Patients with bulky stage Ib2 to IIb cervical squamous cell carcinoma (median age 47 years).", "effective_dosage": "Not applicable (study focused on chemotherapy, not Alanine).", "study_duration": "1-3 courses of chemotherapy (21-day cycles).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.814214+00:00"}
{"study_id": 105563, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the impact of HCV treatment on biochemical markers of liver disease, including alanine aminotransferase levels.", "results_summary": "The study found a significant improvement in biochemical markers of liver disease, including alanine aminotransferase levels, following sustained virological response (SVR) (P < 0.001). HCV genotype, HIV coinfection, cirrhosis, and BMI were predictors of SVR.", "population_specificity": "Patients with chronic HCV, HCV-treatment-naive at enrolment, treated with pegylated interferon-\u03b1 plus ribavirin.", "effective_dosage": "Not specified for alanine aminotransferase.", "study_duration": "Not specified for alanine aminotransferase.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:19.475712+00:00"}
{"study_id": 105573, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to report a rare case of Gianotti-Crosti syndrome (GCS) in an adult and highlight elevated alanine aminotransferase (ALT) levels as part of the condition.", "results_summary": "The study found elevated ALT levels in an adult patient with GCS, which normalized alongside the resolution of skin symptoms over two months. The case suggests GCS may be underrecognized in adults.", "population_specificity": "A 20-year-old woman with Gianotti-Crosti syndrome.", "effective_dosage": "Not specified", "study_duration": "2 months (observation period)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:19.961785+00:00"}
{"study_id": 105574, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of soy supplementation on ALT levels, hepatic steatosis, and insulin resistance in non-diabetic patients with chronic hepatitis C.", "results_summary": "Soy supplementation significantly reduced ALT levels and hepatic steatosis in a subgroup of patients but did not affect insulin resistance. The intervention group had a reduced risk of elevated ALT levels.", "population_specificity": "Non-diabetic patients with chronic hepatitis C (CHC).", "effective_dosage": "32 g/d of protein (soy supplement).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:25.543993+00:00"}
{"study_id": 105576, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the antioxidant status in HCV-infected patients, including the effects of alanine aminotransferase levels before and after antioxidant supplementation.", "results_summary": "Before antioxidant supplementation, alanine aminotransferase levels were significantly increased in untreated HCV patients. Antioxidant supplementation (vitamins E, C, and zinc) reduced oxidative stress markers and improved glutathione levels in both treated and untreated HCV patients.", "population_specificity": "HCV-infected patients (treated and untreated with standard therapy).", "effective_dosage": "Vitamin E (800 mg), vitamin C (500 mg), and zinc (40 mg) daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.922930+00:00"}
{"study_id": 105578, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether short-term exercise could reduce markers of hepatocyte apoptosis, including alanine aminotransferase (ALT), in obese individuals with NAFLD.", "results_summary": "The study found significant decreases in ALT and CK18 fragments, suggesting reduced hepatocyte apoptosis, alongside increased fat oxidation. No significant change in intrahepatic lipid content was observed.", "population_specificity": "Obese individuals with NAFLD (BMI 35.2 \u00b1 1.2 kg/m\u00b2, >5% intrahepatic lipid).", "effective_dosage": "Not applicable (exercise intervention, not alanine supplementation).", "study_duration": "7 consecutive days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.982209+00:00"}
{"study_id": 105575, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to examine the effect of eplerenone (an aldosterone antagonist) on new-onset diabetes in patients with chronic heart failure (CHF) and identify predictors of new-onset diabetes, including serum alanine aminotransferase levels.", "results_summary": "Eplerenone had no significant effect on new-onset diabetes (HR 0.94) or the composite of new-onset diabetes or mortality (HR 0.80). Higher serum alanine aminotransferase was identified as an independent predictor of new-onset diabetes.", "population_specificity": "1,846 initially non-diabetic patients with symptomatically mild CHF (mean age 69, mean left ventricular ejection fraction 26%).", "effective_dosage": "Not specified", "study_duration": "21 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:27.235599+00:00"}
{"study_id": 105577, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of ARB and CCB monotherapy on clinical laboratory parameters, including alanine aminotransferase (ALT), in patients with hypertension and type 2 diabetes mellitus.", "results_summary": "The study found no significant changes in ALT levels for either ARB or CCB users, but did note greater hematological adverse effects and electrolyte imbalances with ARB monotherapy compared to CCB monotherapy.", "population_specificity": "Patients with concomitant mild to moderate hypertension and type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Up to 12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:27.817367+00:00"}
{"study_id": 105580, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To investigate the anti-oxidative and anti-fibrotic effects of aloe vera high molecular weight fractions (AHM) in patients with liver fibrosis.", "results_summary": "AHM significantly reduced liver fibrosis markers (HA, TGF-\u03b2, MMP-2), attenuated liver enzyme activities (ALT, AST, ALP), and decreased inflammation and fibrosis compared to placebo. Hepatic glutathione content decreased in the AHM group, while MDA levels were reduced post-treatment.", "population_specificity": "40 patients with liver fibrosis and 15 healthy controls.", "effective_dosage": "0.15 gm/d AHM", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:28.167678+00:00"}
{"study_id": 105579, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical characteristics of patients with pyogenic liver abscess (PLA) caused by Streptococcus milleri and Klebsiella spp., including risk factors, manifestations, and complications.", "results_summary": "The study found that SM-associated PLA had distinct clinical features, such as a higher incidence of active malignancy and longer symptom duration, compared to Klebsiella spp.-associated PLA. Both types were effectively treated with antibiotics and image-guided aspiration/drainage, with comparable mortality rates.", "population_specificity": "Patients with monomicrobial PLA caused by Streptococcus milleri (n=21) or Klebsiella spp. (n=140) from 2000 to 2009.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:29.507088+00:00"}
{"study_id": 105581, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of adding tocilizumab to methotrexate versus switching to tocilizumab monotherapy in patients with active rheumatoid arthritis (RA).", "results_summary": "The study found no clinically relevant superiority of adding tocilizumab to methotrexate over switching to tocilizumab monotherapy. Both strategies achieved meaningful clinical and radiographic responses, though the combination was more commonly associated with transaminase increases.", "population_specificity": "Adults with active rheumatoid arthritis (DAS28 >4.4) despite methotrexate treatment.", "effective_dosage": "Tocilizumab 8 mg/kg every 4 weeks.", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:34.498602+00:00"}
{"study_id": 105584, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B, not Alanine.", "results_summary": "The study found tenofovir DF was highly effective at suppressing HBV DNA and normalizing ALT levels, but it did not assess Alanine.", "population_specificity": "Adolescents (12 to <18 years) with chronic hepatitis B.", "effective_dosage": "Not applicable (study focused on tenofovir DF, not Alanine).", "study_duration": "72 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:34.766843+00:00"}
{"study_id": 105582, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the pathophysiology, diagnosis, and treatment of Primary Hyperoxaluria Type 1, a disorder involving alanine:glyoxylate aminotransferase deficiency.", "results_summary": "The study found that Primary Hyperoxaluria Type 1 leads to oxalate overproduction, causing renal complications, and that early conservative treatment and combined liver-kidney transplantation in advanced stages are the best management strategies.", "population_specificity": "Patients with Primary Hyperoxaluria Type 1.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:34.838883+00:00"}
{"study_id": 105583, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of mesalazine and sulfasalazine on clinical laboratory parameters, including alanine aminotransferase levels, in patients with inflammatory bowel disease.", "results_summary": "The study found no significant changes in alanine aminotransferase levels in sulfasalazine users, but did not report specific findings for alanine aminotransferase in mesalazine users. The focus was primarily on hematological parameters and urea nitrogen levels.", "population_specificity": "Patients with inflammatory bowel disease (new mesalazine users, n = 303; new sulfasalazine users, n = 67).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:36.055680+00:00"}
{"study_id": 105586, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared the efficacy and hepatic safety of rilpivirine and efavirenz in HIV-infected adults with concurrent HBV/HCV infection.", "results_summary": "Hepatic adverse events were more common and response rates lower in HBV/HCV-coinfected patients treated with rilpivirine or efavirenz compared to non-coinfected patients. The incidence of hepatic adverse events was higher in coinfected patients (26.7%) than in non-coinfected patients (4.1%).", "population_specificity": "Treatment-naive, HIV-infected adults with concurrent HBV and/or HCV infection.", "effective_dosage": "25 mg rilpivirine once daily or 600 mg efavirenz once daily, plus two nucleoside/nucleotide reverse transcriptase inhibitors.", "study_duration": "48 weeks (with safety analysis including data beyond week 48).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:37.430027+00:00"}
{"study_id": 105585, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to determine the safety and efficacy of high-dose radiation therapy with concurrent fixed-dose rate gemcitabine (FDR-G) in unresectable pancreatic cancer, not specifically focused on Alanine.", "results_summary": "The study found that high-dose radiation therapy with FDR-G could be delivered safely, with a recommended dose of 55 Gy. The 2-year freedom from local progression was 59%, and median overall survival was 14.8 months.", "population_specificity": "Patients with unresectable pancreatic adenocarcinoma, performance status 0-2, and specific laboratory criteria.", "effective_dosage": "FDR-G (1000 mg/m\u00b2/100 min intravenously) on days -22, -15, 1, 8, 22, and 29.", "study_duration": "Radiation therapy started on day 1 and was administered over 25 fractions (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:37.594143+00:00"}
{"study_id": 105587, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether adding isoflavone supplementation to exercise training could reduce the risk of non-alcoholic hepatic steatosis in postmenopausal women, as reflected by changes in hepatic enzymes like alanine aminotransferase.", "results_summary": "The study found that exercise training led to favorable changes in hepatic enzymes, with a greater reduction in fatty liver index and \u03b3-glutamyltransferase in the group combining exercise and isoflavones, though other enzymes showed no significant change.", "population_specificity": "Overweight-to-obese postmenopausal women (BMI 28-40 kg/m\u00b2).", "effective_dosage": "Not specified for alanine (study focused on isoflavone supplementation).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:38.082014+00:00"}
{"study_id": 105588, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a research goal related to Alanine.", "results_summary": "The abstract mentions elevated alanine aminotransferase levels as a biochemical characteristic of autoimmune hepatitis but does not discuss Alanine's effects.", "population_specificity": "Patients with autoimmune hepatitis (both adults and children).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:40.875262+00:00"}
{"study_id": 105589, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers investigated the effects of isotretinoin treatment on oxidative stress and liver enzyme levels, including alanine aminotransferase (ALT), in acne vulgaris patients.", "results_summary": "The study found that isotretinoin treatment significantly increased alanine aminotransferase (ALT) levels (p < 0\u00b705), indicating potential liver damage, alongside other oxidative stress markers.", "population_specificity": "31 acne vulgaris patients", "effective_dosage": "0.5-0.7 mg/kg (oral)", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:42.318102+00:00"}
{"study_id": 105590, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to investigate the efficacy, safety, and tolerability of gefitinib as a maintenance treatment in patients with advanced NSCLC, not specifically Alanine.", "results_summary": "The study found that gefitinib significantly prolonged progression-free survival compared to placebo, with common adverse events including rash, diarrhea, and alanine aminotransferase increase. Alanine aminotransferase increase was noted as a common adverse event, but the study did not focus on Alanine's effects.", "population_specificity": "East Asian patients aged 18 or older with advanced NSCLC (stage IIIb or IV) who completed first-line platinum-based chemotherapy without disease progression.", "effective_dosage": "Not applicable (study focused on gefitinib, not Alanine).", "study_duration": "Until disease progression or unacceptable toxic effects (median progression-free survival was 4.8 months for gefitinib).", "interactions": "None mentioned (study focused on gefitinib, not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:45.103997+00:00"}
{"study_id": 105593, "supplement_id": 863, "safety_score": "90", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers investigated the effect of pioglitazone on alanine transaminase (ALT) levels and other biochemical markers in healthy Bengali males to assess liver toxicity and metabolic effects.", "results_summary": "The study found no significant changes in ALT, AST, or other biochemical markers, indicating no liver toxicity or metabolic effects from a single dose of pioglitazone.", "population_specificity": "20 healthy Bengali male volunteers", "effective_dosage": "30 mg single oral dose", "study_duration": "24-hour assessment period", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:47.964177+00:00"}
{"study_id": 105592, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the relationship between AZA metabolite concentrations (including TGNs and MeMPNs), TPMT activity, therapeutic response, and toxicity in adult patients with AIH.", "results_summary": "Higher average TGN concentrations (>220 pmol/8 \u00d7 10(8) RBCs) were associated with remission in AIH patients, while AZA-induced cholestasis was linked to increased MeMPN concentrations. No association was found between TGN, MeMPN, or TPMT activity and leucopenia.", "population_specificity": "Adult patients with autoimmune hepatitis (AIH) prescribed a stable dose of AZA for maintenance of remission.", "effective_dosage": "1.7-2.0 mg/kg/day of AZA", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:48.260746+00:00"}
{"study_id": 105594, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the spontaneous incidence and risk factors of YMDD-motif mutations in lamivudine-na\u00efve chronic HBV carriers, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "The study found that YMDD-motif mutations occur spontaneously in untreated chronic HBV patients with a pooled incidence of 12.21%. Higher HBV DNA copy numbers were associated with increased mutation incidence, but no significant differences were found based on ALT levels (alanine aminotransferase).", "population_specificity": "Chronic HBV patients untreated with lamivudine from eight countries, including China.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:49.840256+00:00"}
{"study_id": 105595, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not studying Alanine; the abstract focuses on lanthanum carbonate's effects on hyperphosphatemia in hemodialysis patients.", "results_summary": "The study did not investigate Alanine; it found that lanthanum carbonate reduced serum phosphate levels and calcium \u00d7 phosphorus product without significant adverse effects, except in patients with preexisting liver disease.", "population_specificity": "Adult hemodialysis patients with serum phosphorus >5.5 mg/dL and on hemodialysis for >1 year.", "effective_dosage": "Not mentioned (study used lanthanum carbonate, not Alanine).", "study_duration": "8 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:52.672403+00:00"}
{"study_id": 105596, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term efficacy and safety of entecavir therapy in Asian patients with chronic hepatitis B, focusing on viral suppression and alanine aminotransferase normalization.", "results_summary": "The study found that 95% of patients achieved hepatitis B virus DNA levels <300 copies/mL, and 76% had normalized alanine aminotransferase levels after 5 years of entecavir therapy. Additionally, 40% achieved HBeAg loss, and 18% underwent HBeAg seroconversion, with no detected resistance to entecavir.", "population_specificity": "Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients with chronic hepatitis B.", "effective_dosage": "Not specified in the abstract.", "study_duration": "5 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.736362+00:00"}
{"study_id": 105597, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "To examine the therapeutic effects and safety of prolonged adefovir dipivoxil (ADV) therapy in children with chronic hepatitis B infection, including its impact on alanine aminotransferase normalization.", "results_summary": "Prolonged ADV treatment demonstrated continued viral suppression and alanine aminotransferase normalization in children with chronic hepatitis B. HBeAg seroconversions were observed in 55 subjects, and the treatment was safe and well-tolerated with minimal resistance.", "population_specificity": "Children with chronic hepatitis B infection.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Up to 192 additional weeks (following an initial 48-week study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:55.091537+00:00"}
{"study_id": 105598, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and effects of LGD-4033 on lean body mass, muscle strength, and hormone levels in healthy men.", "results_summary": "LGD-4033 was well tolerated with no serious adverse events, increased lean body mass dose-dependently, and suppressed certain hormones and lipids, which returned to baseline after discontinuation.", "population_specificity": "76 healthy men aged 21-50 years.", "effective_dosage": "0.1, 0.3, or 1.0 mg daily.", "study_duration": "21 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:55.692997+00:00"}
{"study_id": 105599, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers reviewed recent developments in the evaluation and treatment of chronic hepatitis B (CHB), including the role of elevated alanine aminotransferase in disease progression.", "results_summary": "Elevated alanine aminotransferase levels were noted as a factor in CHB progression, but the abstract does not specifically detail alanine's effects. Antiviral therapies like entecavir and tenofovir were highlighted as effective treatments.", "population_specificity": "Patients with chronic hepatitis B (CHB), including those with coinfection, decompensated cirrhosis, and posttransplant cases.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:56.462047+00:00"}
{"study_id": 105600, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to elucidate the role of alanine-glyoxylate aminotransferase in glyoxylate detoxification and its implications for primary hyperoxalurias.", "results_summary": "The study found that alanine-glyoxylate aminotransferase plays a central role in converting glyoxylate into glycine, preventing oxalate accumulation and associated tissue damage. Genetic defects in this enzyme lead to primary hyperoxalurias, highlighting its critical function in metabolic detoxification.", "population_specificity": "Humans with primary hyperoxalurias or related metabolic disorders.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:57.638726+00:00"}
{"study_id": 105601, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "To investigate the efficacy of fenofibrate combination therapy in improving liver biochemical tests, including alanine transaminase (ALT) levels, in Chinese patients with primary biliary cirrhosis (PBC) who had a partial response to UDCA.", "results_summary": "Fenofibrate combination therapy significantly decreased ALT and AST levels, improved serum triglyceride and cholesterol levels, and normalized ALP in 68% of patients. No obvious adverse effects were observed.", "population_specificity": "Chinese patients with PBC who had a partial response to UDCA monotherapy.", "effective_dosage": "200 mg/day fenofibrate in combination with UDCA (13-15 mg/kg/day).", "study_duration": "At least 6 months (3-month initial assessment).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:01.560630+00:00"}
{"study_id": 105602, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the sustained virologic response (SVR) rates in routine practice versus randomized clinical trials (RCTs) for hepatitis C treatment and identify predictors of SVR, including alanine aminotransferase quotient.", "results_summary": "The study found that alanine aminotransferase quotient was a significant predictor of SVR, ranking fourth in predictive value. SVR rates in routine practice were marginally lower than in RCTs.", "population_specificity": "Scottish patients with hepatitis C virus treated with pegylated interferon and ribavirin.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:02.965649+00:00"}
{"study_id": 105605, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study examined the efficacy and safety of riluzole, not alanine, in treating amyotrophic lateral sclerosis.", "results_summary": "The study found that riluzole 100 mg daily modestly prolonged survival in ALS patients but did not focus on alanine's effects.", "population_specificity": "Adults diagnosed with amyotrophic lateral sclerosis.", "effective_dosage": "Not applicable (study focused on riluzole, not alanine).", "study_duration": "Not specified for alanine.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:03.595987+00:00"}
{"study_id": 105603, "supplement_id": 863, "safety_score": "40", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to assess the long-term safety and efficacy of switching HIV-infected children from a protease-inhibitor-based regimen to a nevirapine-based regimen, focusing on viral suppression and adverse effects, including alanine aminotransferase abnormalities.", "results_summary": "Children switched to nevirapine had better initial CD4 and growth responses but were more likely to develop grade 1-3 alanine aminotransferase abnormalities and virological failure, particularly if non-adherent or with pretreatment drug resistance. Viral-load testing within 52 weeks identified all likely failures, suggesting the switch could be viable with adequate monitoring.", "population_specificity": "HIV-infected children under 24 months previously exposed to nevirapine for prevention of mother-to-child transmission, achieving virological suppression in Johannesburg, South Africa.", "effective_dosage": "Not specified (doses adjusted per growth at each visit).", "study_duration": "Median follow-up of 156 weeks (range: 90\u2013232 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.536852+00:00"}
{"study_id": 105604, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether \u03c9-3 fatty acid-supplemented parenteral nutrition (PN) improved alanine aminotransferase levels and liver injury in post-liver transplant patients compared to traditional PN.", "results_summary": "PUFA treatment significantly improved alanine aminotransferase levels, reduced hepatic cell injury, decreased infectious morbidities, and shortened hospital stays compared to traditional PN. The prognostic nutrition index and prealbumin levels also showed significant improvements in the PUFA group.", "population_specificity": "Patients with end-stage liver disease or hepatic cellular carcinoma undergoing orthotopic liver transplantation.", "effective_dosage": "Not specified (isocaloric and isonitrogenous PN for 7 days).", "study_duration": "7 days post-surgery.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.903513+00:00"}
{"study_id": 105606, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of laquinimod, including its effects on alanine aminotransferase levels, in patients with relapsing-remitting multiple sclerosis.", "results_summary": "The study found that laquinimod reduced relapse rates and disability progression in multiple sclerosis patients, but transient elevations in alanine aminotransferase levels were observed in 5% of patients receiving laquinimod.", "population_specificity": "Patients with relapsing-remitting multiple sclerosis (n=1106) across 24 countries.", "effective_dosage": "0.6 mg once daily", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.904214+00:00"}
{"study_id": 105607, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the safety and feasibility of S-1 versus UFT/LV as adjuvant chemotherapy for stage III colon cancer, not specifically to evaluate Alanine.", "results_summary": "The study found that both S-1 and UFT/LV had manageable safety profiles, with differing adverse event patterns. Alanine aminotransferase increases were more common with UFT/LV, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 20-80 years with curatively resected stage III colon cancer.", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "5 courses (35-day cycles) for UFT/LV, 4 courses (42-day cycles) for S-1.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:09.654854+00:00"}
{"study_id": 105608, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of aerobic exercise and/or progressive resistance training in modulating liver fat and alanine aminotransferase (ALT) levels in adults.", "results_summary": "The study found a significant benefit of exercise therapy on liver fat, even with minimal or no weight loss, but no effect on ALT levels. The pooled effect size for liver fat reduction was modest (ES=-0.37).", "population_specificity": "Adults, particularly those with disorders characterized by fatty liver.", "effective_dosage": "Not specified (exercise interventions varied).", "study_duration": "Not specified (duration of exercise interventions varied).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:10.220155+00:00"}
{"study_id": 105591, "supplement_id": 863, "safety_score": "80", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic potential of Spirulina platensis, including its effects on alanine aminotransferase (ALT) levels, in patients with chronic hepatitis C virus infection.", "results_summary": "Spirulina treatment led to significant improvements in ALT levels, CLDQ, and ASEX scores compared to Silymarin, though virological response differences were not statistically significant. The study suggests Spirulina may have therapeutic potential for chronic HCV patients.", "population_specificity": "66 patients with chronic hepatitis C virus infection.", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:10.714095+00:00"}
{"study_id": 105609, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether intrahepatic lactate and pyruvate levels could detect ischemia and rejection in transplanted livers earlier than standard methods.", "results_summary": "The study found that elevated lactate levels were associated with both ischemia and rejection, while increased pyruvate levels were specific to rejection. These measurements allowed earlier detection of complications compared to traditional markers like alanine aminotransferase and bilirubin.", "population_specificity": "Patients with liver transplants (12 grafts with rejection, 9 with ischemia, and 39 uneventful grafts as reference).", "effective_dosage": "Not specified", "study_duration": "Median monitoring period of 10 days post-operation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:11.870359+00:00"}
{"study_id": 105611, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the behavior of laboratory parameters, including alanine aminotransferase (ALT), in athletes to improve the interpretation of clinical chemistry data in sports medicine.", "results_summary": "The study noted that ALT is mainly released from the liver in athletes, and its serum concentration can be influenced by intense exercise, requiring careful interpretation alongside other liver markers like AST and bilirubin.", "population_specificity": "Athletes engaged in intense and continuous exercise, training, and competitions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.624192+00:00"}
{"study_id": 105612, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare clinicopathological features of extrahepatic cholangiocarcinoma in non-jaundiced versus jaundiced patients, including serum alanine aminotransaminase levels.", "results_summary": "The study found statistically significant differences in preoperative serum alanine aminotransaminase levels between non-jaundiced and jaundiced patients with extrahepatic cholangiocarcinoma, but did not evaluate alanine's therapeutic effects.", "population_specificity": "50 patients resected for extrahepatic cholangiocarcinoma (15 non-jaundiced, 35 jaundiced).", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:14.961912+00:00"}
{"study_id": 105613, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of entecavir in treating chronic hepatitis B, particularly focusing on virological, biochemical, and serological responses in HBeAg-positive and HBeAg-negative patients.", "results_summary": "The study found that entecavir monotherapy resulted in a rapid and significant reduction in viral load, with 83% of patients achieving a virological response by week 48. A significant correlation was observed between early virological response (week 12) and seroconversion to anti-HBe at week 48.", "population_specificity": "190 nucleos(t)ide-naive chronic hepatitis B patients (73% male, 84% Caucasian, 30% HBeAg-positive) from 25 Spanish centers.", "effective_dosage": "0.5 mg/day", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:16.518884+00:00"}
{"study_id": 105614, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether dietary intake of alanine differentially associates with blood pressure in patients with prevalent cardiovascular disease.", "results_summary": "The study found that higher intake of alanine was associated with increased odds of higher systolic and diastolic blood pressure, with odds ratios of 1.17 and 1.22 per quartile of intake, respectively. These associations were statistically significant but modest in effect size.", "population_specificity": "Patients with prevalent cardiovascular disease participating in a study comparing low-fat versus Mediterranean-style diets.", "effective_dosage": "Not specified (analyzed by quartiles of intake).", "study_duration": "2 years (with assessments at baseline, 3 and 6 months, and every 6 months thereafter).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:18.249933+00:00"}
{"study_id": 105615, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of combined antiviral and immunosuppressant therapy in adult hepatitis B virus-associated glomerulonephritis (HBV-GN) patients, with secondary outcomes including blood levels of alanine aminotransferase.", "results_summary": "The study found that combined therapy significantly reduced proteinuria and increased serum albumin without significant alterations in liver or renal function, and no significant activation of HBV-DNA replication. Alanine aminotransferase levels were monitored as a secondary outcome, but no specific effects on alanine were highlighted.", "population_specificity": "Adult patients with hepatitis B virus-associated glomerulonephritis (HBV-GN).", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:19.185952+00:00"}
{"study_id": 105617, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether overnight glucose infusion reduces renal ammoniagenesis driven by alanine uptake in decompensated cirrhotic patients.", "results_summary": "Overnight glucose infusion significantly lowered glucagon levels and attenuated the hyperammonaemia induced by simulated upper gastrointestinal bleed, reducing renal ammoniagenesis compared to fasting.", "population_specificity": "Patients with decompensated cirrhosis", "effective_dosage": "20% glucose solution administered over 12 hours", "study_duration": "12 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:19.266024+00:00"}
{"study_id": 105616, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the long-term safety and treatment outcomes of pegvisomant in patients with acromegaly, not specifically Alanine.", "results_summary": "The study found that pegvisomant was generally safe and effective, with a low incidence of serious adverse events and normalization of IGF-I levels in 63.2% of subjects after 5 years. Elevated liver enzymes (including alanine aminotransferase) were reported in 2.5% of patients, but no liver failure occurred.", "population_specificity": "Patients with acromegaly treated with pegvisomant.", "effective_dosage": "Mean dose of 18 mg/d.", "study_duration": "Mean treatment duration of 3.7 years, with follow-up for 2.1 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:20.135546+00:00"}
{"study_id": 105619, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between HLA genotypes and lapatinib-associated liver injury, including the role of alanine aminotransferase (ALT) elevation.", "results_summary": "The study found that HLA-positive cases had higher ALT elevation, while HLA-negative cases showed a higher incidence of Gilbert's syndrome, suggesting a genetic link to lapatinib-associated liver injury.", "population_specificity": "Patients with HER2-positive metastatic breast cancer treated with lapatinib.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:21.834536+00:00"}
{"study_id": 105618, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify simple clinical indicators to exclude or detect cirrhosis in adults with known or suspected liver disease, including the role of alanine aminotransferase (ALT) in diagnostic scores.", "results_summary": "The study found that combinations of laboratory tests, including ALT (as part of the Lok index and Bonacini cirrhosis discriminant score), were useful for identifying or excluding cirrhosis. A Lok index <0.2 (incorporating ALT) significantly lowered the likelihood of cirrhosis (LR, 0.09).", "population_specificity": "Adult patients with known or suspected liver disease (19,533 patients, including 4,725 with biopsy-proven cirrhosis).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:21.914873+00:00"}
{"study_id": 105610, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy of oral budesonide on liver function tests, including alanine aminotransferase (ALT), in patients with primary sclerosing cholangitis (PSC) and pouchitis.", "results_summary": "The study found no significant change in ALT levels after budesonide treatment, indicating no impact on liver function tests. However, there was significant improvement in afferent limb and pouch inflammation.", "population_specificity": "18 pouch patients with underlying ulcerative colitis (UC) and PSC.", "effective_dosage": "9 mg daily for 1-3 months, followed by 3-6 mg maintenance for another 9 months.", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:22.125721+00:00"}
{"study_id": 105620, "supplement_id": 863, "safety_score": "40", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the feasibility and safety of induction chemotherapy followed by gefitinib and thoracic radiotherapy in patients with unresectable locally advanced adenocarcinoma of the lung, including monitoring alanine aminotransferase elevations.", "results_summary": "Grade 3-4 alanine aminotransferase elevations were observed in 37.1% of patients during the chemoradiation phase, indicating significant liver toxicity. The overall treatment feasibility was not met, but toxicity was deemed acceptable.", "population_specificity": "Patients with unresectable locally advanced adenocarcinoma of the lung.", "effective_dosage": "Not specified for alanine; gefitinib was administered at 250 mg daily.", "study_duration": "Gefitinib was administered for 1 year; TRT lasted from days 57-98.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:25.423217+00:00"}
{"study_id": 105622, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not attempting to determine anything about Alanine; the study focused on pazopanib's efficacy and safety for treating renal cell carcinoma.", "results_summary": "The study did not investigate Alanine; it evaluated pazopanib's effects on renal cell carcinoma, including progression-free survival and adverse events.", "population_specificity": "Patients with metastatic renal cell carcinoma.", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "Not applicable (Alanine not studied).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:26.423554+00:00"}
{"study_id": 105621, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether telbivudine, which affects alanine aminotransferase (ALT) levels, could prevent vertical transmission of hepatitis B virus (HBV) in pregnant women with chronic hepatitis B.", "results_summary": "Telbivudine significantly reduced HBV DNA levels, normalized ALT, and prevented perinatal transmission without causing adverse events in mothers or infants. Treated mothers showed higher rates of HBV DNA suppression and ALT normalization compared to controls.", "population_specificity": "HBeAg-positive pregnant women with chronic hepatitis B, HBV DNA >6 log(10) copies/mL, and elevated ALT levels.", "effective_dosage": "Not specified in the abstract.", "study_duration": "From the 2nd or 3rd trimester until postpartum week 28.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:26.479265+00:00"}
{"study_id": 105623, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers aimed to report a rare case of oxaliplatin-induced grade 3/4 hepatocellular injury and ototoxicity, not specifically to evaluate Alanine.", "results_summary": "The study found that oxaliplatin, not Alanine, caused grade 3/4 hepatocellular injury and ototoxicity in a patient, with symptoms and liver enzyme elevations recurring upon reintroduction of the drug.", "population_specificity": "A 46-year-old female with stage IIIC adenocarcinoma of the sigmoid colon.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:27.041395+00:00"}
{"study_id": 105624, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were investigating the antitumor efficacy and safety of miriplatin infusion therapy for small hepatocellular carcinomas (HCCs), not specifically Alanine.", "results_summary": "The study found that miriplatin infusion therapy had a 31% overall response rate (1 complete and 3 partial responses out of 13 patients) for small HCCs, with no severe hematological toxicity but some grade 3/4 increases in liver enzymes (AST and ALT).", "population_specificity": "Patients with small HCCs (\u22642 cm) judged inadequate for curative treatment.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Treatment occurred between March 2010 and September 2010, with efficacy evaluated at 4-8 weeks and overall evaluation >3 months post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:29.213102+00:00"}
{"study_id": 105627, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy and safety of lamivudine (LAM) in preventing vertical transmission of HBV and normalizing ALT levels in pregnant women.", "results_summary": "LAM treatment significantly reduced HBV DNA levels and prenatal transmission rates compared to controls, while normalizing ALT levels without increasing congenital malformation risks.", "population_specificity": "Pregnant women with normal or abnormal ALT levels, HBeAg-positive, and high HBV DNA levels.", "effective_dosage": "100 mg daily", "study_duration": "From the 24th to 32nd week of gestation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:29.420332+00:00"}
{"study_id": 105626, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers discussed the efficacy and safety of acetylcysteine in treating acetaminophen overdose, including the rationale behind dosing regimens and the limitations of current nomograms for predicting hepatotoxicity.", "results_summary": "The abstract notes that acetylcysteine has been used successfully for acetaminophen overdose since the 1970s, but optimal dosing and duration remain unclear. Some patients still develop hepatic damage, particularly with delayed treatment.", "population_specificity": "Patients with acetaminophen overdose (specific demographics not detailed).", "effective_dosage": "Not specified (oral and IV dosing regimens mentioned but no exact amounts).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.053441+00:00"}
{"study_id": 105625, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of methotrexate (MTX) and chloroquine (CQ) in treating articular and cutaneous manifestations of systemic lupus erythematosus (SLE), with incidental observations on alanine aminotransferase levels.", "results_summary": "The study found that low-dose MTX was as effective as CQ for SLE manifestations, with a rise in serum alanine aminotransferase observed in two MTX cases but none in the CQ group. No significant differences in most outcome measures were noted between the two treatments, except for morning stiffness (favoring MTX) and ESR (favoring CQ).", "population_specificity": "SLE patients with articular and cutaneous manifestations.", "effective_dosage": "Not specified for alanine (study focused on MTX at 10 mg weekly and CQ at 150 mg daily).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.256463+00:00"}
{"study_id": 105628, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine the frequency of adverse effects and serum minimum toxic concentration of Methotrexate (MTX) in Rheumatoid Arthritis (RA) patients, with alanine transaminase as one of the measured markers.", "results_summary": "The study found that 27% of RA patients developed MTX toxicity, with hepatotoxicity (8.6%) and hematological problems being the most common adverse effects. Serum MTX concentration of 0.71 \u03bcmol/l was identified as a toxic cutoff with 71% sensitivity and 76% specificity.", "population_specificity": "140 adult RA patients (68 males, 72 females) receiving low-dose MTX.", "effective_dosage": "10 mg/week MTX.", "study_duration": "At least 3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:34.666555+00:00"}
{"study_id": 105629, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers evaluated variations in laboratory parameters, including alanine amino transferase (ALT), in psoriasis patients receiving systemic treatments to assess potential adverse effects.", "results_summary": "Methotrexate and infliximab were associated with increased risk of more than doubling the upper normal ALT values (odds ratios 2.38 and 1.74, respectively), indicating potential liver-related adverse effects.", "population_specificity": "First-time recipients of continuous systemic psoriasis treatment in Italian public referral centers (n = 10,539).", "effective_dosage": "Not specified", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.244473+00:00"}
{"study_id": 105630, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of licorice root extract on liver enzyme levels (specifically ALT and AST) in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that licorice root extract significantly reduced ALT and AST levels in the case group compared to the placebo group, with statistically significant results (p < 0.001). However, BMI changes were not significant in either group.", "population_specificity": "66 patients with NAFLD, elevated liver enzymes, and increased liver echogenicity on sonography.", "effective_dosage": "2 g aqueous licorice root extract per day (one capsule).", "study_duration": "2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.836131+00:00"}
{"study_id": 105631, "supplement_id": 863, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the long-term safety and efficacy of teriflunomide, including its effects on alanine aminotransferase levels, in patients with relapsing forms of multiple sclerosis.", "results_summary": "The study found that asymptomatic alanine aminotransferase increases were common but mostly mild, with no serious opportunistic infections or discontinuations due to infection. Alanine-related effects were dose-dependent, with higher doses showing a favorable safety profile over up to 8.5 years.", "population_specificity": "Patients with relapsing forms of multiple sclerosis (RMS).", "effective_dosage": "7 mg/day and 14 mg/day.", "study_duration": "Mean duration of 5.6 years (range: 0.05-8.5 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.910983+00:00"}
{"study_id": 105632, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review bioanalytical procedures for determining markers of ethanol consumption during pregnancy, including alanine aminotransferase (ALT), as part of assessing prenatal ethanol exposure.", "results_summary": "The abstract mentions alanine aminotransferase (ALT) as one of the classical biomarkers for alcohol-induced pathology, but it does not provide specific findings about ALT's effects or performance in the study. The focus is on evaluating various biomarkers for detecting gestational alcohol exposure.", "population_specificity": "Pregnant women and their fetuses/newborns.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.887507+00:00"}
{"study_id": 105633, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify factors associated with severe liver fibrosis in hospitalized diabetic patients, including elevated alanine aminotransferase levels.", "results_summary": "Elevated alanine aminotransferase was associated with severe liver fibrosis in univariate analysis, but not in multivariate analysis. The study found a 15.5% prevalence of severe fibrosis in diabetic patients.", "population_specificity": "Hospitalized patients with type 1 or 2 diabetes.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:37.065032+00:00"}
{"study_id": 105634, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the usefulness of transient elastography (TE) in assessing liver fibrosis stages and disease progression in primary biliary cirrhosis (PBC), comparing it to biochemical markers including alanine aminotransferase (ALT).", "results_summary": "TE demonstrated high performance in diagnosing liver fibrosis stages and was superior to biochemical markers like AST/ALT ratio. Liver stiffness progression was stable in noncirrhotic PBC patients but increased significantly in cirrhotic patients, predicting poor outcomes.", "population_specificity": "Patients with primary biliary cirrhosis (PBC), including a diagnostic cohort of 103 patients and a monitoring cohort of 150 patients.", "effective_dosage": "Not specified", "study_duration": "Up to 5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:38.902915+00:00"}
{"study_id": 105635, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to compare the non-lipid effects, including alanine aminotransferase elevation, of rosuvastatin-fenofibrate combination therapy versus rosuvastatin monotherapy in high-risk Asian patients with mixed hyperlipidemia.", "results_summary": "The study found that alanine aminotransferase elevation was greater in the rosuvastatin monotherapy group compared to the combination group, though the incidences of hepatotoxicity were similar between the two groups. The combination therapy showed higher elevations in other markers like homocysteine and serum creatinine.", "population_specificity": "High-risk Asian patients with mixed hyperlipidemia.", "effective_dosage": "Rosuvastatin 10 mg plus fenofibrate 160 mg or rosuvastatin 10 mg alone.", "study_duration": "24 weeks of drug treatment followed by 4 weeks post-discontinuation.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:43.568057+00:00"}
{"study_id": 105636, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The study aimed to investigate the effect of CPAP treatment on regional adipose tissue distribution and liver enzymes, including alanine aminotransferase, in patients with obstructive sleep apnoea.", "results_summary": "The study found no significant change in alanine aminotransferase levels (1.34 U\u00b7L(-1); p=0.59) between therapeutic and sham CPAP treatments, indicating no effect of CPAP on this enzyme.", "population_specificity": "Patients with moderate or severe obstructive sleep apnoea (n=27 with complete MRI/MRS data).", "effective_dosage": "Not specified for alanine.", "study_duration": "2 months per treatment arm (therapeutic and sham CPAP) with a 1-month washout.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:44.787857+00:00"}
{"study_id": 105637, "supplement_id": 863, "safety_score": "80", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to assess the beneficial and harmful effects of bezafibrate (not Alanine) in patients with primary biliary cirrhosis, either alone or in combination with ursodeoxycholic acid (UDCA).", "results_summary": "Bezafibrate significantly decreased serum alkaline phosphatases and plasma immunoglobulin M compared to no intervention, but had no significant effect on mortality, liver-related morbidity, or adverse events. Mixed results were observed for other liver biochemistry measures, with some effects potentially attributable to bias or random errors.", "population_specificity": "151 Japanese patients with primary biliary cirrhosis.", "effective_dosage": "Not specified (any dose or regimen).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.740127+00:00"}
{"study_id": 105639, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study examined the efficacy and tolerability of rosuvastatin, not Alanine.", "results_summary": "The study found rosuvastatin to be safe and effective in reducing lipid fractions, but no results specific to Alanine were reported.", "population_specificity": "Patients intolerant to other conventional statin regimens, aged 63\u00b110 years, 50% male, with various comorbidities.", "effective_dosage": "Not applicable (study focused on rosuvastatin, not Alanine).", "study_duration": "Median follow-up of 14.9 months (range 3-79 months).", "interactions": "None mentioned (study focused on rosuvastatin, not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.010055+00:00"}
{"study_id": 105640, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the effects of sorafenib on hepatic markers, including alanine aminotransferase, in patients with hepatocellular carcinoma.", "results_summary": "The study found that sorafenib was safe and effective for hepatocellular carcinoma regardless of baseline alanine aminotransferase levels, with no notable differences in safety profiles between patients with normal or elevated levels. Hepatic function remained stable during sorafenib therapy.", "population_specificity": "Patients with hepatocellular carcinoma (n=602) categorized by baseline hepatic marker concentrations.", "effective_dosage": "Not specified", "study_duration": "Measured at baseline and on day 1 of each treatment cycle (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.681754+00:00"}
{"study_id": 105638, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of combining direct-acting antiviral agents (daclatasvir and asunaprevir) with or without peginterferon alfa-2a and ribavirin in patients with chronic HCV genotype 1 infection who had not responded to prior therapy.", "results_summary": "The study found that 36% of patients receiving only the two direct-acting antiviral agents achieved a sustained virologic response, while 100% of those receiving the combination with peginterferon and ribavirin achieved this response. Transient elevations in alanine aminotransferase levels were noted in some patients.", "population_specificity": "Patients with chronic HCV genotype 1 infection who had not responded to prior therapy with peginterferon and ribavirin.", "effective_dosage": "Daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily), with or without peginterferon alfa-2a and ribavirin.", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.919935+00:00"}
{"study_id": 105642, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers reviewed the use of adefovir dipivoxil (ADV) for treating chronic hepatitis B, including its efficacy, safety, and role in patients with lamivudine resistance.", "results_summary": "ADV 10 mg daily improved liver histology, reduced HBV DNA and ALT levels, and promoted HBeAg seroconversion, but newer drugs like tenofovir and entecavir showed greater efficacy. ADV was generally well tolerated but carried a low risk of nephrotoxicity.", "population_specificity": "Chronic HBV-infected patients, both HBeAg-positive and -negative, including those with lamivudine resistance.", "effective_dosage": "10 mg daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.641396+00:00"}
{"study_id": 105641, "supplement_id": 863, "safety_score": "70", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of pemetrexed, including its impact on alanine aminotransferase levels, as a second-line treatment for advanced/metastatic osteosarcoma.", "results_summary": "Elevated alanine aminotransferase was observed in 9.4% of patients as a grade 3/4 toxicity. The treatment showed minimal efficacy, with only 3.1% partial response and 15.6% stable disease rates.", "population_specificity": "Patients with high-grade advanced/metastatic osteosarcoma (median age 43.3 years, 90.6% with lung metastases).", "effective_dosage": "500mg/m\u00b2 pemetrexed administered on day 1 of 21-day cycles.", "study_duration": "Not explicitly stated, but follow-up included progression-free survival (median 1.4 months) and overall survival (median 5.5 months).", "interactions": "Folic acid and vitamin B12 supplementation were used alongside pemetrexed.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.809805+00:00"}
{"study_id": 105643, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were attempting to determine whether transient elastography (TE) could identify patients with chronic liver disease at risk of clinical decompensation, not specifically evaluating Alanine.", "results_summary": "The study found that TE had high predictive accuracy (AUC 0.87) for clinical outcomes in chronic liver disease, outperforming liver biopsy and other variables. A combined model including TE, AST/ALT ratio, and MELD score yielded the highest predictive accuracy (Harrell's C 0.93).", "population_specificity": "Patients with chronic liver disease (n=667).", "effective_dosage": "Not mentioned", "study_duration": "Median follow-up of 861 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:51.619856+00:00"}
{"study_id": 105645, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of adefovir dipivoxil (ADV) monotherapy versus combination ADV and lamivudine (LAM) therapy in treating LAM-resistant chronic hepatitis B (CHB).", "results_summary": "Combination therapy showed no clear advantage over monotherapy in short durations but demonstrated significantly better biochemical and virological responses when treatment exceeded 12 months.", "population_specificity": "Patients with LAM-resistant chronic hepatitis B (CHB).", "effective_dosage": "Not specified", "study_duration": "Varied (3, 6, 12, and >12 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:53.353902+00:00"}
